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Numerous studies have demonstrated that aberrant expressions of specific microRNAs 
(miRNAs) are involved in many cancer types including colorectal cancer (CRC). In 
particular, in a previous study we integrated miRNA and target gene expression data obtained 
from chip array by comparing normal colon tissue, primary tumor and liver metastasis, and 
we focused our attention on post-transcriptional regulatory networks with differentially 
expressed miRNAs and their supported relations with target genes. We demonstrated that 
miR-182 was one of the most up-regulated miRNAs in primary CRC compared to normal 
colon mucosa. 
Starting from these premises, the project was focused on the following tasks: 
1) Identification of miRNA biomarkers for CRC monitoring and screening in colon cancer 
patients; 
2) Analysis of the functional effects of miR-182 inhibition in CRC cell lines characterized by 
a different in vivo tumorigenic behavior. 
Regarding the first task in my first year of PhD we published a paper (68, Appendix 1) to 
confirm the involvement of miR-182 in CRC development and progression. In particular, a 
total of 240 histopathological and 51 plasma samples were included in this study. We 
observed a significant overexpression of miR-182 in CRC primary tumor compared to normal 
colon mucosa, which is also maintained in CRC liver metastases. Then, we also demonstrated 
that plasma miR-182 levels are significantly higher in CRC patients than in healthy controls. 
Moreover, miR-182 plasma levels were significantly reduced in post-operative samples after 
radical hepatic metastasectomy, compared to pre-operative samples. These results indicated
that the evaluation of circulating miR-182 levels could be a promising approach to improve 
the repertoire of non-invasive blood based biomarkers for CRC monitoring and screening. 
To strengthen these evidences, we carried out a prospective study in stage I-II (N0 M0) colon 
cancer. We preselected four strongly up-regulated miRNAs involved in the same post-
transcriptional sub-network (miR-18a, miR-21, miR-182 and miR-183) and the most down-
regulated miRNA (miR-139) and we confirmed that all the selected miRNAs are significantly 
modulated in colon cancer compared to normal colon mucosa. Moreover, we observed that 
miR-182, miR-183 and miR-139 were not modulated in inflammatory tissue compared to 
colon mucosa; by contrast miR-18a and miR-21 are significantly up-regulated also in the 




inflammation-related process. To investigate whether the selected miRNAs could be useful to 
predict tumor relapse the patients were subdivided in Recurrent and Non Recurrent groups 
within 55 months. We calculated 10 ratios between the expression values of all possible 
miRNA pairs, applying the miRNA ratio approach both in the tumor tissue and in the adjacent 
normal mucosa. None of the miRNA ratios resulted predictive when evaluated in the colon 
cancer tissue, instead three miRNA ratios evaluated in the tumor-adjacent mucosa were found 
to be significant predictors of relapse by 55 months from resection: miR-21/miR-183, miR-
18a/miR-182 and miR-18a/miR-183. Manuscript submitted.
Regarding the second task, to gain insights in the functional role played by miR-182 in the 
tumorigenesis we investigated the effects of miR-182 inhibition. To this end, we used two 
CRC cell lines as in vitro models: MICOL-14h-tert (an in vivo non-tumorigenic cell line 
derived from a lymph node metastasis of rectal cancer) and its in vivo tumorigenic variant 
MICOL-14tum (or TC22). We carried out transfection experiments for the transient inhibition 
of miR-182 and we observed a significant increase of cell apoptosis in both cell lines after the 
treatment. We confirmed the results with cleaved PARP and Caspase-3 proteins detection by 
Western Blot.
Therefore, we evaluated the effect of miR-182 inhibition on in vivo tumor growth. To this 
end, we injected subcutaneously the TC22 cells treated with the anti-miR-182 in NOD/SCID 
mice and, after a week, we performed also an in vivo intra-tumor injection of miR-182 
inhibitor to maintain the silencing. Interestingly, the inhibition of miR-182 significantly 
reduced the size of the tumor, and the obtained mass exhibited a pattern of features as less 
aggressive tumors compared to controls. Manuscript in preparation. 
In conclusions: 
? miR-182 expression levels can be followed in tissues and plasma of CRC patients. In 
particular, circulating miR-182 evaluation could be a promising approach to enhance the 
repertoire for blood based biomarkers in non-invasive CRC monitoring and screening; 
? the panel of selected miRNAs were significantly regulated also in the early phases of the CRC 
tumor process extending to stage I-II the results obtained in our previous work in stage IV 
CRC;
? not a single miRNA, but rather a coordinated alteration of four miRNAs may be useful to 
predict recurrence after resection in early CRC when evaluate in the normal mucosa adjacent 
to tumor; 




? in CRC cell lines the expression level of miR-182 is higher in in vivo tumorigenic variant, 
suggesting a role of this miRNA in tumor aggressiveness. MiR-182 seems to be involved in 
increasing the survival of cancer cells and enhance the tumor growth. 









1. Colorectal cancer 
1.1 Epidemiology of CRC. Colorectal cancer (CRC) is still one of the most worldwide 
cancer type, in both men and women (1). The relative survival rate for CRC is 65% at 5 years 
following diagnosis and 58% at 10 years. Only 39% of CRC patients are diagnosed with 
localized-stage disease, for which the 5-year survival rate is 90%; survival declines to 71% 
and 14% for patients diagnosed with regional and distant stages, respectively (American 
Cancer Society: Cancer Facts and Figures 2017-2019. Atlanta). CRC incidence is higher in 
developed regions compared to less developed regions, which may reflect an increased 
exposure to risk factors such as smoking, unhealthy diet, physical inactivity, obesity, and 
other lifestyle factors (3). The opposite is observed for mortality rates and is mainly caused by 
late diagnosis due to lack of symptoms at an early stage, and thus many patients present at 
diagnosis with advanced disease and metastasis. Despite the ongoing development of novel 
anti-tumor agents and therapeutic principles as we enter the era of personalized cancer 
medicine, systemic chemotherapy continues to be the cornerstone for treatment of CRC 
patients (4).  
1.2 Classification and disease staging. The TNM Classification of Malignant Tumours 
(TNM) is a cancer staging notation system that describes the stage of a cancer which 
originates from a solid tumor with alphanumeric codes and it is the most widely used and 
recommended system for CRC staging (5). TNM classification is based on the extent of the 
disease at diagnosis, which provides an important estimation of prognosis in CRC (6). It 
includes clinical findings (cTNM) and radiologic imaging (rTNM) prior to diagnosis, and 
pathological examination of resected tumor specimens or perioperative findings (pTNM, or 
ypTNM) when staging is made after neoadjuvant treatment) (7). Specifically, the T stage 
describes the depth of invasion of the primary tumor through the layers of the intestinal wall, 
N stage describes spread to regional lymph nodes, and the M stage describes the occurrence 
of distant metastases. TNM stages are classified in stage groups (stage I-IV) where increasing 
stage corresponds to a more advanced disease, e.g. lymph node involvement (stage III) and 
metastasis (stage IV) (8). In particular: 




Stage 0: The cancer is found only in the innermost lining of the colon or rectum. “Carcinoma 
in situ” is considered to be Stage 0 colon cancer.
Stage I: The tumor has grown into the inner wall of the colon or rectum. The tumor has not 
grown through the wall. 
Stage II: The tumor extends more deeply into or through the wall of the colon or rectum. It 
may have invaded nearby tissue, but cancer cells have not spread to the lymph nodes. 
Stage III: The cancer has spread to nearby lymph nodes, but not to other parts of the body. 
Stage IV: The cancer has spread to other parts of the body, such as the liver or lungs. 
Based on microscopic features, CRCs are graded in terms of resemblance to the tissue from 
which it originated and the proportion of gland formation by the tumor (9). Tumor 
differentiation grade range from highly differentiated tumors with >95% gland formation, to 
undifferentiated tumors with less than 5% glandular structures. Histopathological 
differentiation grade is an important prognostic factor in CRC as low differentiation grade is 
associated with poorer outcome (10, 11). 
1.3 Molecular basis of CRC. During colorectal adenocarcinoma development, epithelial 
cells from gastrointestinal trait acquire sequential genetic and epigenetic mutations in specific 
oncogenes and/or tumor suppressor genes, conferring them a selective advantage on 
proliferation and self-renewal (12). Normal epithelium becomes hyper-proliferative mucosa 
and subsequently gives rise to a benign adenoma that evolves into carcinoma and metastasis 
in about 10 years (13). Sporadic CRC, due to somatic mutations, account for about 70% of all 
CRCs. 
Normal gastrointestinal epithelium is organized along a crypt-villus axis. A pool of colon 
stem and progenitor cells, the most undifferentiated cell types that are able of self-renewal and 
pluripotency, are located at the bottom of the crypt. These cells migrate along the crypt-villus 
axis, simultaneously differentiating in all epithelial colon lineages, such as Paneth, goblet, 
enterocytes and enteroendocrine cells (14). In about two weeks they arrive at the top of the 
villus and undergo apoptosis (15, 16). This process is orchestrated from gradients of proteins, 
such as Wnt, BMP and TGF-β, together with extracellular matrix and stromal cells that form 
the cell niche (17).  
At the molecular level, CRCs are a very heterogeneous group of diseases as consequence of 
multistep tumorigenesis of several genetic and epigenetic events (Figure 1). The well known 




“adenoma-carcinoma” sequence in CRC has made this disease a popular model for a multihit 
cancer (18). There are three most important molecular pathways leading to CRC 
development: 1) Somatic or germ line derived genomic instability due to inactivation of 
several tumor suppressor genes such as APC, SMAD4 and TP53; aberrant DNA methylation, 
DNA repair defects induced by mutations in mismatch repair genes (MMR); 2) Mutational 
inactivation of tumor suppressor genes (e.g., APC, TP53, TGFβ, and MMR genes); and 3) 
Over activation of oncogenic pathways including BRAF, RAS (KRAS and NRAS), 
Phosphatidylinositol 3-kinase (PIK-3) (19). 
In colorectal epithelial cell transformation play a significant role other involved mechanisms, 
as chromosomal instability (CIN), microsatellite instability (MSI), CpG island methylator 
phenotype (CIMP), DNA polymerase mutations (POLE), aberrant DNA methylation and 
DNA repair defects (20-23). These alterations confer individual susceptibility to cancer, and 
are responsible for responsiveness or resistance to antitumor agents. 
As regard, an international consortium named CRC Subtyping Consortium (CRCSC) 
dedicated to large-scale data sharing recently suggests a disease stratification to resolve 
inconsistencies among the reported gene expression and facilitate clinical translation (24). 
The result is in four consensus molecular subtypes (CMSs) of CRC with distinguishing 
features: 
CMS1 (MSI immune, 14%): hypermutation, MSI, and strong immune activation. 
CMS2 (Canonical, 37%): epithelial, with CIN and prominent WNT and MYC signaling 
activation. 
CMS3 (Metabolic, 13%): epithelial, with metabolic dysregulation. 
CMS4 (Mesenchymal, 23%): with prominent TGF-β activation, stromal invasion and 
angiogenesis. 
A remaining 13% possibly represent a transition phenotype or intratumoral heterogeneity. 
This is considered the most robust classification system currently available for CRC. 




Figure 1: A multihit scenario for colorectal cancer, showing the mutational events that correlates with 
each step of “adenoma-carcinoma” sequence. CRC development is a multistep process that begins when 
normal epithelium forms aberrant crypts and further advances into stages of early and late adenomatous polyps, 
invasive carcinoma, and metastasis. Some of the most frequently affected genes and pathways are shown. The 
arrows show the oncogenes that are turned on, while the red blocked arrows denote the tumor suppressor genes 
that are turned off at different stages of CRC development. APC, adenomatous polyposis coli; COX2, 
cyclooxygenase 2; DCC, deleted in colorectal cancer; EGFR, epithelial growth factor receptor; MLH1, 2, mutL 
homologue (mismatch repair) genes; MSH2, 3, 6, mutS homologue (mismatch repair) genes; TP53, multi-
function tumour-suppressor gene; PRL3, (also known as PTP4A3, a metastasis-associated gene); Ras, signalling 
protein; SMAD3 and SMAD4, signalling proteins downstream of TGFbeta; TGFbeta, transforming growth 
factor beta; TGFbetaRII, transforming growth factor receptor beta type II. (from Thergiory Irrazábal et al., The 
Multifaceted Role of the Intestinal Microbiota in Colon Cancer. 2014).




1.4 Biomarkers in CRC. The continuing CRC incidence and the increasing disease 
associated morbidity and mortality are in part due to the lack of efficient early detection; 
therefore, earlier diagnosis and more efficient treatment could play a key role in reducing 
CRC mortality. Obviously, there is an urgent need for reliable biomarkers with prognostic and 
predictive value, which are able to discriminate cancer patients from healthy individuals, as 
well as different CRC subgroups from each other. 
Cancer related molecular and cellular markers can be classified as: 
Diagnostic markers, used for risk stratification and early detection; 
Prognostic marker, give an indication of the likely progression of the disease; 
Predictive markers, predict treatment response; 
Surveillance markers, used to monitor disease recurrence. 
As summarized in Figure 2, several biomarker classes have been evaluated in CRC screening 
and have all shown potential in early phase biomarkers studies: MSI, CIN, DNA mutations, 
KRAS mutations, BRAF mutations, TP53 mutations, APC/β catenin mutations, DNA 
methylation (aberrant DNA hypermethylation, genome-wide DNA hypomethylation), tumor 
specific gene or microRNA expression pattern, telomere length dynamics, angiogenesis 
biomarkers, inflammatory biomarkers, stool and blood non-invasive biomarkers (circulating 
tumor cells, cell-free DNA, microRNA and proteins) (19). In particular, these last biomarkers 
derived from biological fluids and so easily accessible could be considered as practical tools 
for CRC detection and monitoring to improve patients’ prognosis, treatment response 
prediction and possible recurrence risk. 
Actually, the most widely used biomarker in CRC is CEA (carcinoembryonic antigen), a set 
of highly related glycoproteins involved in cell adhesion that are secreted from cancer cells 
into the bloodstream. Elevated levels at diagnosis are associated with increased tumor stage a 
poor prognosis (25), but the test is compromised by low sensitivity and specificity and high 
rate of false positive. Indeed, CEA levels are lower in early stage, and high levels are found in 
other cancer types, non-malignant conditions, and smokers (26-29), making it insufficient for 
early detection and screening. In addition, other circulating proteins are often measured, as 
carbohydrate antigens (CA19-9, CA50, CA72-4), soluble Fas ligand (FasL), p53, and VEGF. 




Despite the disadvantages, CEA is the more non-invasive and inexpensive test with a strong 
prognostic impact useful to monitor CRC patients (30). 
Figure 2: Different classes of colorectal cancer associated molecular and cellular biomarkers. (from 
Aghagolzadeh P et al . Molecular and cellular biomarkers for CRC). 
Therefore, new biomarkers are needed to early identify colon cancer patients. In particular, 
they should be able to stratify patients into risk groups to support the therapeutic choice. The 
evaluation of biomarkers in body fluids of cancer patients will be in the next future a novel 
mini-invasive tool for an earlier personalized cancer diagnosis and to predict prognosis and 
response to therapy of CRC. 





2.1 miRNAs biogenesis. MiRNAs are small non-coding RNAs that function as guide 
molecules in RNA silencing. Targeting most protein-coding transcripts, miRNAs are involved 
in nearly all developmental and physiological processes. The biogenesis is regulated at 
multiple levels and is under tight temporal and spatial control, and their dysregulation is 
associated with many human diseases, particularly cancer. MiRNAs genes are generally 
transcribed by RNA polymerases II and III, generating precursors that undergo a series of 
cleavage events to form mature miRNA. As described in Figure 3, the conventional 
biogenesis pathway consists of two cleavage events, one nuclear and one cytoplasmic (31). 
The transcription by RNA Polymerase II (Pol II) in the nucleus forms large pri-miRNA 
transcripts, which are capped and polyadenylated. These pri-miRNA transcripts are processed 
by the RNase III enzyme DROSHA and its co-factor, PASHA, to release the ~70-nucleotide 
pre-miRNA precursor product. RAN–GTP and exportin 5 transport the pre-miRNA into the 
cytoplasm and subsequently, another RNase III enzyme, DICER, processes the pre-miRNA to 
generate a transient ~22-nucleotide miRNA: miRNA duplex. This duplex is then loaded into 
the miRNA-associated multiprotein RNA-induced silencing complex (miRISC), which 
includes the Argonaute proteins, and the mature single-stranded miRNA is preferentially 
retained in this complex. Then, the mature miRNA binds to complementary sites in the 
mRNA target to negatively regulate gene expression by grade of complementarity between 
the miRNA and its target gene. miRNAs that bind with imperfect complementarity block 
target gene expression at the level of protein translation usually affect mRNA stability and 
bind in the 3’ UTRs. Instead, miRNAs that bind to their mRNA targets with perfect (or nearly 
perfect) complementarity induce target-mRNA cleavage and were generally found in the 
coding sequence or open reading frame (ORF) of the target (32).  
Non-canonical pathways for miRNA biogenesis, including those that are independent of 
Drosha or Dicer, are also emerging (33).




Figure 3: Overview of canonical miRNA biogenesis pathway. MiRNA genes are transcribed as primary 
miRNAs (pri-miRNAs) by RNA polymerase II (Pol II) in the nucleus. The long pri-miRNAs are cleaved by 
Microprocessor, which includes DROSHA and DiGeorge syndrome critical region 8 (DGCR8), to produce the 
60–70-nucleotide precursor miRNAs (pre-miRNAs). The pre-miRNAs are then exported from the nucleus to the 
cytoplasm by exportin 5 (XPO5) and further processed by DICER1, a ribonuclease III (RIII) enzyme that 
produces the mature miRNAs. The functional strand of the mature miRNA is loaded together with Argonaute 
(Ago2) proteins into the RNA-induced silencing complex (RISC), where it guides RISC to silence target 
mRNAs through mRNA cleavage, translational repression or deadenylation, whereas the passenger strand 
(black) is degraded. 




2.2 miRNAs in CRC. miRNAs are critical regulators of gene expression. Amplification and 
overexpression of individual 'oncomiRs' or genetic loss of tumour suppressor miRNAs are 
associated with human cancer and are sufficient to drive tumorigenesis in mouse models. 
Moreover, global miRNA depletion caused by genetic and epigenetic alterations in 
components of the miRNA biogenesis machinery is oncogenic. Aberrant miRNA biogenesis 
in cancer occurs at different steps during miRNA maturation: genetic alterations, epigenetic 
modifications, oncogenes and tumour suppressors negatively or positively regulate pri-
miRNA transcription. Numerous oncogenic mutations are recently identified in core miRNA 
biogenesis genes (34) (Figure 4), but there are multiple mechanisms by which cancer cells 
inactivate the miRNA ‘guardian’ of differentiation, proliferation and metabolic 
reprogramming. This, together with the recent identification of novel miRNA regulatory 
factors and pathways, highlights the importance of miRNA dysregulation in cancer. 
Figure 4: Dysregulated miRNA biogenesis in cancer. Aberrant miRNA biogenesis in cancer occurs at 
different steps during miRNA maturation.




MiR-143 and miR-145 were the first miRNA associated with CRC. Michael and colleagues 
observed a significant down-regulation of these miRNAs in tumor tissue compared to normal 
tissue (35), which was later shown to elicit tumor suppressor activity (36) and mainly 
expressed in the stroma (37). Since then, a range of altered expressed miRNAs has been 
associated with development and progression of this tumor type. 
In CRC, miRNAs have shown involvement in, or directly regulating, oncogenic signaling 
pathways, such as Wnt, Ras, TGF-β, and NF-kB/AKT/STAT3 (38). In addition, they are also 
involved in the regulation of the stemness of cancer cells, epithelial-mesenchymal transition 
(EMT), and metastasis (Figure 5).
Figure 5: Genes frequently mutated in CRC and their relationships with miRNAs. Oncogenic miRNAs are 
depicted in blue, tumor-suppressive miRNAs in red, and miRNAs with reported pleiotropic effects in purple. 
Direct relationships are shown with solid lines, while indirect relationships are illustrated with dotted lines. The 
Wnt pathway is augmented by miR-135b, miR-21 and miR-155, and inhibited by miR-34a, miR-29b/c. 
Downstream of Wnt, MYC transcriptionally activates the miR-17-92 locus, but represses expression of miR-15, 
miR-26 and miR-30. KRAS augments expression of miR-31. In the PI3K pathway, which is negatively regulated 
by PTEN, miR-135b is augmented by PI3K inhibition of FoxO transcription factors. MiR-221, miR-21 and miR-
17/106 enhance activation of PI3K signaling by repressing negative regulators of this pathway. MiRNAs also 
modulate inflammatory pathways mediated by the transcription factors NFΚB and STAT3 by directly inhibiting 
IL-6 (via Let-7 miRNAs, which are inhibited by LIN28B) or the IL-6 receptor (via miR-34 and miR-125b). 
MiR-221/222 and miR-29b/c can also augment this pathway via indirect stimulatory effects on IL-6, NFΚB, and 
STAT3. The TGF-β pathway is also antagonized by several miRNAs, including miR-17/106, miR-135b, and 
miR-20a through effects on TGFBR2 and SMAD4. The miRNA miR-93 can stimulate the TGF-β pathway by 
repressing the inhibitory SMAD7, although the effect of miR-93 is inhibitory of Wnt signaling through 
inhibition of SMAD7, which can augment nuclear accumulation of β-catenin. Lastly, several miRNAs have 
effects on EMT in CRC tumorigenesis, with miR-15/16 and miR-34 inhibiting this process, while miR-21
enhances EMT. CC, cell cycle. 




2.3 miRNAs as diagnostic and prognostic tools. Screening and early detection of cancer is 
the main approach for prevention. MiRNAs are observed to function in positive- or negative-
feedback loops highlighting their relevance in self-sustaining epigenetic switches that can 
change or reinforce cellular aberrant phenotype. As consequence, they are undoubtedly strong 
drivers and modulators of colon tumorigenesis with a potential as biomarkers and therapeutic 
targets. 
Studies on the prognostic value of miRNAs have demonstrated their association with 
clinicopathological features of CRC patients. MiR-21 is a highly relevant miRNA in CRC and 
its up-regulation have been related to decreased disease-free survival (39) and suggested also 
as blood-based biomarker (40). Other miRNAs that have been demonstrated to correlate with 
poor survival rates are miR-185, miR-221, miR-182, miR-17-3p, miR-34a, miR-106a, when 
expressed at high levels, and miR-133b, miR-150, miR-378, when down-regulated (41-47). 
Moreover, potential miRNAs biomarkers to predict metastasis and recurrence are also 
indicated: miR-10b, miR-885-5p, miR-210, and miR-155 (48, 49). Since several alterations 
confer individual susceptibility to cancer, and are responsible for responsiveness or resistance 
to antitumor agents, it is crucial to identify biomarkers to predict the effect of chemotherapy 
allowing a more personalized approach to the management of CRC. Several miRNAs have 
been associated with a different response to chemotherapy, as miR-21, miR-320a, miR-150 
and miR-129 (50-53). 
Biomarker discovery for CRC based on the personalized genotype and clinical information 
could facilitate the classification of patients with certain types and stages of cancer to tailor 
preventive and therapeutic approaches. These cancer-related biomarkers should be highly 
sensitive and specific in a wide range of specimens as tumor tissues, patients’ fluids or stool.
Reliable biomarkers, which enable the early detection of CRC, could improve early diagnosis, 
prognosis, treatment response prediction, and recurrence risk. 




3. Previous results obtained in our lab 
3.1 miRNA regulatory network in colorectal carcinogenesis and metastasis 
In our previous studies (54) we analyzed the expression profiles in 158 samples from 46 
patients with CRC and we identify changes in both miRNA and gene expression levels among 
normal colon mucosa, primary tumor and liver metastasis samples. We observed that most 
changes in miRNA and gene expression levels had already established in the primary tumors 
and they remain almost stably in the subsequent primary tumor-to-metastasis transition. 
Specifically, while only few mRNAs were found to be differentially expressed between 
primary colorectal carcinoma and liver metastases, miRNA expression profiles can classify 
primary tumors and metastases well. A preliminary survival analysis considering 
differentially expressed miRNAs (DEM) suggested a possible link between miR-10b 
expression in metastasis and patient survival. In addition, we integrated expression data 
obtained from chip array by comparing normal colon mucosa, primary tumor and CRC liver 
metastasis, and we focused our attention on post-transcriptional regulatory networks with 
DEM, and their supported relations with target genes. Indeed, we identified a combination of 
interconnected miRNAs, which are organized into sub-networks, including several regulatory 
relationships with differentially expressed genes and specific mixed circuits with transcription 
factors. 
In particular, two network components are observed involving respectively 6 up-regulated and 
17 down-regulated DEM. The component regarding 6 up-regulated miRNAs was smaller, but 
a large fraction of genes appeared to be modulated by miR-182 (miR-182-5p; sequence: 
UUUGGCAAUGGUAGAACUCACACU). Other miRNAs upregulated in the same network 
were miR-18a (miR-18a-5p; sequence: UAAGGUGCAUCUAGUGCAGAUAG), miR-18b 
(miR-18b-5p; sequence: UAAGGUGCAUCUAGUGCAGUUAG), miR-183 (miR-183-5p;
sequence: UAUGGCACUGGUAGAAUUCACU), miR-21 (miR-21-5p; sequence: 
UAGCUUAUCAGACUGAUGUUGA), and miR-1246 (sequence: 
AAUGGAUUUUUGGAGCAGG) (Figure 6). Interestingly, the large majority of miRNAs
and genes with varied expression in the comparison among primary tumors and normal tissue 
remained stable after metastasis development. This similarity in miRNAs expression in later 
stage of tumor progression may reflect the need to maintain the tumor-specific processes 
required for tumorigenesis and cancer progression. So, we described the interplay of miRNA 
groups in regulating gene expression important for tumor development, and demonstrated that 




miR-182 was one of the most up-regulated miRNA in primary CRC compared to normal 
colon tissue. 
Figure 6: Post-transcriptional regulatory network of miRNAs up-modulated in primary CRC tumor vs
normal colon mucosa contrast. The network represents DEMs up-modulated in tumor vs normal mucosa 
comparison (red triangles), supported target genes (circles) and their relations (gray dotted lines). Target DEGs 
are shown in blue, other genes in grey. The pink solid line outlines the experimentally validated miR-
182/ENTPD5 relation. 




3.2 MICOL-14 and MICOL-14tum, a model of tumor dormancy and its tumorigenic 
variant 
The MICOL-14h-tert (or MICOL-14) cell line was derived from a metastatic colorectal cancer 
(55) and was initially unstable because telomerase-negative, although their parental tumor 
tissue sample score as hTERT-positive. Dalerba P. et al demonstrated that the lack of 
telomerase activity was due to lack of hTERT transcription and that the reconstitution of 
telomerase enzymatic activity in this unstable CRC primary culture by transduction with an 
hTERT-encoding retroviral vector allows immortalization of these short-lived cultures. This 
cell line contained mutations in APC and KRAS, and more importantly, the set of detected 
mutations corresponded to that of the original tumor tissue proving that the primary culture 
was representative of the tumor cell population that formed the original in vivo metastatic 
tumor mass. 
As previously reported (56), MICOL-14 cells remained viable, although poorly tumorigenic 
in non-obese diabetic severe combined immunodeficient (NOD/SCID) mice following 
subcutaneous injection. A tumorigenic variant of MICOL-14 cells, termed MICOL-14tum (or 
TC22), was obtained from Indraccolo S. group after subcutaneous injection of parental 
MICOL-14 cells in Matrigel plus angiogenic factors. As consequence, this cell variant was 
able to generate large vascularized tumors by 6 weeks from injection (Figure 7A) and this 
feature may in part depend on the higher angiogenic potential of MICOL-14tum compared with 
MICOL-14 cells (Figure 7B). As reported by Serafin V. et al. (57), in agreement with this, 
the numbers of Ki67+ proliferating cells were significantly higher in aggressive than in 
dormant tumors (Figure 7C). Moreover, it seems that the activation and increased expression 
of several components of Notch pathway is a feature of aggressive xenografts. Instead, the 
apoptosis levels were low and comparable in both tumor entities. 




Figure 7. MICOL-14 and MICOL-14tum exhibited different tumorigenic capacities in NOD/SCID mice. A. 
MICOL-14 cells behaved as dormant when injected into the subcutaneous tissue of the mice, whereas their 
tumorigenic variant MICOL-14tum, formed aggressive tumors. B. MICOL-14tum showed an high angiogenic 
potential as were able to generate large vascularized mass. C. The numbers of Ki67+ proliferating cells were 
significantly higher in aggressive than in dormant tumors. 
To confirm whether the cell lines have maintained the original different biological behavior 
we initially carried out the experiment of subcutaneous injection of  MICOL-14h-tert and 
MICOL-14tum (or TC22) in mice. We observed that MICOL-14 cells behaved as dormant, 
instead TC22 developed aggressive tumors (Figure 8).  




Figure 8. MICOL-14h-tert and TC22 confirmed their different in vivo biological behaviour. The volume of 
tumors were significantly different after s.c. injection of the CRC cell lines.
3.3 MICOL-14h-tert and TC22 present the same STR profiling 
The Short Tandem Repeat (STR) profile is one of the most useful methods used to compare 
specific loci on DNA from two or more samples. A STR is a microsatellite and the 
polymorphic nature of the STR regions that are analyzed intensifies the discrimination 
between one DNA profile and another. So, we analyzed the profile of CRC cell lines to obtain 
a specific genetic fingerprint, which permit us to monitor them in the time and avoid cell line 
misidentification (58, 59). DNA profiles of the CRC cell lines studied were reported in 
Supplementary Table 1. Notably, MICOL14h-tert and its tumorigenic variant TC22 present 
the same STR loci number, thus confirming that these cell lines have the same origin. 




AIMS OF THE PhD PROJECT: 
miRNAs are optimal biomarkers owing to high stability under storage and handling 
conditions and their presence in body fluids. The detection of circulating miRNA levels has 
the potential for an earlier cancer diagnosis and to predict prognosis and response to therapy.
We demonstrated that miR-182 was one of the most up-regulated miRNAs in primary CRC 
compared to normal colon mucosa, and a large fraction of genes appears to be modulated by 
this miRNA. 
Starting from these premises, my PhD project was focused on the following tasks: 
1) Identification of miRNA biomarkers for monitoring and screening of colon cancer patients. 
To this end, we investigating plasma, and both matched normal colon mucosa and tumor 
tissues in carcinogenesis cascade.  
Furthermore, we focused on the localized colon cancer (pTNM stage I/II, N0 M0) because 
within 5 years from surgery up to 20% of these patients develop extranodal metastases and no
predictive biomarker able to identify the population at high-risk of relapse after curative 
treatment is presently available. 
2) Analysis of the functional impact of miR-182 inhibition on CRC cell lines characterized by 
a different in vivo tumorigenic behavior. In particular, we used MICOL-14h-tert and TC22 cells 
as CRC model of tumor dormancy and its tumorigenic variant, respectively. We also 
investigated the effect of miR-182 inhibition on in vivo TC22 cell growth. We extended the 
analysis to explore the transcriptome profiles and regulatory mechanisms involved in miR-
182 modulation. 








MATERIALS AND METHODS 
Task 1 
Patients. Forty-eight patients with stage I-II colon adenocarcinomas, who underwent radical 
surgical treatment between January 2003 and October 2008, were selected from the 
institutional database where clinico-histopathological data of all patients were recorded. The 
surgical procedure was standardized according to the cancer’s location, minimizing any 
variability in technique. Pathological cancer staging (pTNM) was done according to the 7th
Edition of the TNM classification. This study focuses on patients at TNM stages I or II, with 
no regional lymph node metastases (N0) and no distant metastases (M0), and none of them 
received neoadjuvant or adjuvant therapy.
In order to reduce variability, it was mandatory to exclude: patients with a known history of a 
hereditary colorectal cancer syndrome, rectal cancers, cases with special histotype, in situ
carcinomas. 
Consistently with patients’ follow-up (recurrence and survival data) two groups were 
collected and Recurrence-free survival (RFS) was defined as the length of time from radical 
primary tumor resection until the detection of loco-regional or distant recurrence or decease 
due to any cause: 
-Recurrent (R) group: 23 patients with RFS less than 55 months; 
-Non-Recurrent (NR) group: 25 patients with RFS greater than 55 months; 
All patients were followed up every 6 months for the first 2 years after their surgical treatment 
and every 12 months from the 3rd to the 5th year thereafter. Further patients’ details are 
reported in Table 1.
Finally, also 10 patients affected by a form of Inflammatory Bowel Disease (IBD), in 
particular moderate Ulcerative Colitis (UC), were independently evaluated. 
Approval for the use of all human tissues was obtained from the research Ethics Commitee of 
the University Hospital of Padua and informed consent was obtained from all the patients 
involved. 
The collection and selection of patients were performed in collaboration with Professor 
Rugge’s group (Surgical Pathology and Cytopathology Unit, DIMED, University of Padova).




Characteristics  R NR
   n=23 n=25
Age at resection (years) Median 72 69
 Range 55-85 50-90
Sex M 16 (70%) 10 (40%)
 F 7 (30%) 15 (60%)
Tumor site Cecum, colon ascending, hepatic (right) flexure 7 6
 transverse colon 3 4
 Splenic (left) flexure, colon descending,  
sigmoid colon 
13 15
 Rectum 0 0
TNM stage I 6 7
 II 17 18
T(n) T1 2 1
 T2 4 6
 T3 15 18
 T4 2 0
N(n) N0 23(100%) 25(100%)
M(n) M0 23 (100%) 25 (100%)
Grading (n) G1 5 4
 G2 15 17
 G3 3 4
 G4 0 0
Table 1: Clinical characteristics of relapsing (R) and non-relapsing (NR) patients. 
Histopathological FFPE samples. All the considered samples were fixed in formalin for 18-
24h. Original slides or serial sections (4-6 μm thick) obtained from archival paraffine-
embedded tissue samples were jointly re-assessed by two expert gastrointestinal pathologists 
according to current criteria (WHO 2010). For each patient, a sample of CRC-adjacent, 
morphologically normal colon mucosa was dissected from the proximal tumor resection 
margin, with a minimum distance of 3 centimeters from the primary tumor. At least 3 cancer 
samples were obtained from all the cases considered (range 3-8, depending on the size of the 
cancer).  
RNA isolation and quantitative RT-PCR. Hematoxylin and eosin (H&E) stained sections of 
each specimen were prepared and evaluated, and only samples with more than 70% of vital 
tumor tissue were considered for RNA extraction. Total RNA was isolated from FFPE 




(Formalin Fixed Paraffin Embedded) samples using the RecoverAll Total Nucleic Acid 
Isolation Kit (Ambion, Austin, TX), according to the manufacturer’s instructions, and 
optimizing the protocol for ensure the recovery of smaller RNA fragments as miRNAs. The 
concentration of RNA was quantified by NanoDrop 1000 Spectrophotometer (NanoDrop 
Technologies, Waltham, MA). 
Total RNA was used for first-strand cDNA synthesis in a 15μl reaction volume, using the 
TaqMan miRNA Reverse Transcription kit and miRNA-specific stem-loop primers (Thermo 
Fisher Scientific, Foster City, CA, USA). We performed qRT-PCR experiments amplifying 
cDNA for 45 cycles using TaqMan miRNA primers and probes (Thermo Fisher Scientific) 
and LightCycler 480 PCR Master Mix (Roche Diagnostics, Mannheim, Germany). All 
reactions were conducted in triplicates, including no template controls, using LightCycler 480 
II Real-Time System (Roche Diagnostics).  
Data normalization.  RNU44 and miR-200c were tested as candidate normalizers. MiR-200c, 
already identified as most stable miRNA in metastatic CRC (54), was confirmed as best 
normalizer also in localized CRC. Relative expression of target miRNAs was calculated as 
ΔCtmiR = CtmiR - Ctnormalizer. The miRNA ratio (60, 61) was used to find molecular markers of 
relapse.  The ?? value of each miRNA was converted into the corresponding expression level 
(2-Ct)? The miRNA ratios between all possible miRNA pairs (e.g. miR-x/miR-y ratio) were 
calculated as 2-ΔCt = 2-(CtmiR-x – CtmiR-y). 
Statistical analysis. A one-tailed Wilcoxon signed-rank sum test was used to identify 
miRNAs significantly different between matched tumor tissue and adjacent normal mucosa. A 
univariate logistic regression model was built to evaluate the ability of each miRNA ratio on 
log2-scale to predict the relapse by 55 months. Odds ratios and 95% confidence intervals were 
estimated for the fitted logistic regression models. Receiver operating characteristic (ROC) 
curves were plotted and the area under the ROC curve (AUC) was estimated to compare the 
most significant miRNA ratios.  
Statistical analysis were performed in the R environment using a customized code and the 
pROC package for ROC curve analysis. 
Data normalization and statistical analysis were performed in collaboration with Dott. A. 
Grassi (Oncology and Immunology Division, DiSCOG, University of Padova).





Cell lines and in vitro culture. The classical immortalized human colorectal adenocarcinoma 
cell lines Caco2 and HT29 were purchased from Banca Biologica and Cell Factory Core 
Facility of IRCCS AOU San Martino - IST Istituto Nazionale per la Ricerca sul Cancro - 
Genova. MICOL-14h-tert and CG-758 cell lines were a gift from Dalerba P. group, instead the 
tumorigenic variant MICOL-14tum (named also TC22) were obtained and characterized in our 
Department from Indraccolo S. lab. 
The cells were grown in RPMI-1640 medium (Invitrogen, Milan, Italy) supplemented with 
10% fetal bovine serum (FBS; Gibco, Invitrogen), L-glutamine, Pen/Strep and HEPES, and 
used within 6 months from thawing and resuscitation. The cells were harvested with trypsin-
EDTA in their exponentially growing phase and maintained in a humidified incubator at 37 
°C with 5% CO2. 
RNA extraction, reverse transcription and quantitative RT-PCR analysis. RNAs were 
extracted from cells after 24, 48 and 72h of transfection using Trizol reagent (Thermo Fisher 
Scientific), according to the manufacturer’s instructions. RNA concentration and purity were 
measured with Nanodrop (Bio-Tek Instruments, Winooski, VT, USA) and Agilent (Agilent
Technologies, Santa Clara, CA, USA).  
To study miRNA expression levels, the Taqman microRNA reverse transcription synthesis 
Kit and miRNA-specific stem-loop primers (Thermo Fisher Scientific) were used according 
to the manufacturer’s instructions. 
First-strand cDNA synthesis from total RNA (1μg) was performed using the SuperScript™ II 
Reverse Transcriptase kit (Thermo Fisher Scientific) to detect and quantify mRNA.  
A LightCycler 480 PCR Master Mix (Roche Diagnostics) was used with specific Taqman 
assay to detect miRNAs or transcripts. The Lightcycler II (Roche) instrument was used for 
realtime PCR experiments for 40 cycles and the relative expression level was calculated using 
the 2-ΔΔCT method. Expression data were normalized using as reference RNU44 for miRNAs, 
and HPRT1 for genes.
Transient transfection for in vitro miRNA silencing. Cells were plated at the concentration 
of 1,5x105 cells/well on normal adhesion 6-well dishes with RPMI complete medium for 24h. 
Then, the RPMI medium was replaced with Opti-MEM® I Reduced Serum Medium (Thermo 




Fisher Scientific) and specific anti-miR (hsa-mir-182, or hsa-miR-183) mirVana™ miRNA 
inhibitor (Ambion by Thermo Fisher Scientific) was added to a total of 150 pmol/well; to 
allow cell transfection, Lipofectamine RNAiMAX transfection reagent (Invitrogen) was 
mixed with the miRNA inhibitor, as protocol instructions. The mixture was incubated in a 
dark room for 5 min at room temperature and then added to each well. Similarly, an equal 
number of cells were treated with an anti-miR-NC (mirVana™ miRNA inhibitor Negative 
Control #1; Ambion), to use as a control for data normalization on anti-mir-182 or anti-miR-
183 independent transfection effects. Moreover, to monitor antagomiR uptake efficiency by 
flow cytometry analysis, the same number of cells were transfected with a 
carboxyfluorescein-labeled RNA oligonucleotide (FAM™-labeled Anti-miR™ Negative 
Control; Ambion). After an overnight incubation, the Opti-MEM medium supplemented with 
miRNA inhibitors was replaced with normal complete RPMI medium, and the miRNA 
silencing was evaluated by qRT-PCR at time point considered. At each time point the cells 
were also harvested to perform all the experiments for miRNA function investigation. In all 
reported silencing experiments, transfection efficiency was highest than 80%, and miRNA 
expression levels showed a significant decrease in transfected cells compared to controls. The 
controls for all the experiments were: Non-Treated (NT) cells and anti-miR-NC treated cells. 
In particular, the NT cells were plated in the medium used for the transfection, but without 
treatments. 
Apoptosis and cell cycle assay, flow cytometry. For the detection of apoptosis and necrosis, 
an Annexin-V-FLUOS staining kit (Roche, Mannheim, Germany) was used according to the 
manufacturer's instructions. Briefly, the cells were seeded in triplicate in six-well plates at a 
density of 1.5×105 cells per well in RPMI with 10% FBS. After 24 h incubation, the 
procedure was performed at 24, 48 and 72 h after transfection. Also the cell culture medium 
containing floating cells was collected. Adherent cells were rinsed with PBS and collected 
after trypsin-EDTA incubation. After the cells were visibly detached, at least 5 ml of 
complete growth medium was added and cells were resuspended. Afterward, both floating 
and adherent cells were pooled and rinsed twice with PBS. The resulting suspension was 
poured into a flow cytometry tube and centrifuged for 5 min at 200 g at 4 °C. Then, the cell 
pellets were resuspended in 100 μl incubation buffer with 2 μl Annexin-V and 2 μl propidium 
iodide (PI) for 15 min in a dark room at 4 °C. For cell cycle analysis, cells were fixed with 
cold ethanol and then incubated for 1 h in a PI/RNAse solution. The method is based on 




cellular DNA content, which discriminates resting/quiescent cell populations (G0 cells) and 
quantifies cell cycle distribution (G1, S or G2/M, respectively). Then, the samples were 
analyzed by using a FACS Calibur flow cytometer (Becton-Dickinson Immunocytometry 
Systems) with excitation/emission wavelengths of 488/525 and 488/675 nm for Annexin-V
and PI, respectively.  
Migration assay. Cells were plated into 6-well dishes, transfected after 24h, and allowed to 
grow for another 24h, after which a scratch was created. A scratch was applied directly on the 
monolayer by means of a sterile pipette tip. The ability of cells to move and fill in the gap was 
evaluated by optical microscopy immediately (0hr) and at 18-24-36hr after the scratch. Data 
represents mean ± standard deviation (SD) from three independent experiments. 
Western blot analysis. Cell lysates were obtained into RIPA buffer containing protease 
inhibitor. Proteins were quantified using Quantum Micro Protein Assay Kit (Euroclone, 
Milan, Italy). Lysates were denatured, boiled and then fractionated using SDS-PAGE gel 
(Invitrogen). After blotting onto PVDF membrane and blocking with a 5% non-fat dry milk or 
BSA solution, blots were incubated at 4°C with the primary antibody overnight. The 
following rabbit primary antibodies from Cell Signaling Technology, were used: Cleaved 
Caspase-3 #9661 1:1000, PARP #9542 1:1000. Mouse antibody vs β-actin (sc-47778 1:1000 
Santa Cruz Biotechnologies, CA, USA) served as an internal control. Antibody binding to the 
membrane was detected using a secondary antibody (goat anti-rabbit IgG 1?5000; Perkin 
Elmer or goat anti-mouse IgG 1?5000 Calbiochem) conjugated to horseradish peroxidase and 
visualized using Supersignal West Pico Chemiluminescent Substrate Kit (Thermo Fisher 
Scientific) with the Chemidoc XRS System (Bio-Rad) and Quantity One 4.6.9 software (Bio-
Rad, CA, USA). Densitometric analysis was performed with the ImageJ software (NIH). Data 
are shown as the mean ± SD of the mean of three different experiments performed in 
triplicate. Results are representative of three independent experiments.  
In vivo tumorigenesis assay. Nonobese diabetic/severe combined immunodeficiency
(NOD/SCID) mice were obtained from internal breeding. Procedures involving animals and 
their care conformed to institutional guidelines that comply with national and international 
laws and policies (EEC Council Directive 86/609, OJ L 358, 12 December 1987). TC22 cells 
were seeded in complete medium and treated with miR-182 inhibitor or anti-miR-NC. For 




tumor establishment, 7-wk-old to 9-wk-old mice were injected subcutaneously (s.c.) with 
exponentially growing TC22 NT or treated cells washed and resuspended in PBS. 1x106 cells 
in a 200μl total volume were inoculated in combination with Matrigel in both dorsolateral 
flanks. 
After 1 week the mirVana™ miR-182 inhibitor in vivo ready (Life Technologies by Thermo 
Fisher Scientific) or negative control combined with Invivofectamine 2.0 Reagent (Life 
Technologies) were used for intratumoral injection to maintain the in vivo miRNA silencing. 
The resulting tumor mass were inspected twice weekly and measured by caliper. Tumor 
volume was calculated with the following formula: tumor volume (mm3) = L X l2 X 0.5, 
wherein L is the longest diameter, l is the shortest diameter, and 0.5 is a constant to calculate 
the volume of an ellipsoid. At the end of the experiments the mice were sacrificed by cervical 
dislocation and the tumors were harvested by dissection and either snap-frozen or fixed in 
formalin and embedded in paraffin for further analysis. H&E staining were performed using 
automated system. This part was performed in collaboration with Dott. M. Curtarello of the S. 
Indraccolo’s group (Oncology and Immunology Division, DiSCOG, University of Padova,). 
In addition we investigated the CRC Grading and Mitotic index of tumor mass. The 2010 
WHO scores the CRC Grading in G1 well differentiated cancer, G2 moderate differentiated 
cancer and G3 poorly differentiated cancer based upon the percentage of glands formation (> 
75%; 35%-75% and <35%, respectively). Main growth patterns are, in order from tipically 
less aggressive to more aggressive: glandular, trabecular and solid. Mitotic index is the 
number of mitosis counted in 10 fields at 40X magnification (n. x10 hpf). Usually, a typical 
CRC has a mean mitotic index higher than 20 mitosis x10hpf. This part was performed in 
collaboration with Dott. L. Albertoni of the Professor Rugge’s group (Surgical Pathology and 
Cytopathology Unit, DIMED, University of Padova). 
Statistical analysis. Student’s t-test was performed on parametric groups. Values were 
considered significant at *p ≤ 0.05 and **p ≤ 0.01. Values are reported as mean ± SD. All 
analysis were performed by using SigmaPlot (Systat Software Inc). 
Gene expression analysis. Human gene expression microarray data were generated using the 
Affymetrix GeneChip PrimeView Human Gene Expression Array (Affymetrix by Thermo 
Fisher Scientific). Total RNA, after specific quality controls, was isolated from MICOL-14h-
tert and TC22 transfected with anti-miR-182 or anti-miR-NC. For transcriptome analysis, we 




performed 4 chip array for each cell line condition. Statistical and bioinformatic analysis were 
conducted to find out significant gene expression differences due to miR-182 inhibition. Raw 
data quality controls has been performed using the R package ‘affyQCreport’ (62) to examine 
and compare boxplots and histograms of intensities, percent present call rate and 3’/5’ 
hybridization intensity ratios. 
Expression matrix reconstruction was obtained by ‘affy’ package (63) using RMA for data 
summarization and normalization (background correction, quantile normalization, log-
transformation of values). Dataset description was based on different unsupervised analyses 
providing on sample correlation values (Pearson correlation method, complete clustering 
method) and PCA analyses. Additional cluster analyses and heatmaps (Pearson correlation 
method, complete cluster method) of selected sample and gene subsets were obtained using R 
package ‘gplots’.
Transcript-level annotation of probesets, based on Ensembl (release 88), was obtained with R 
package ‘primeviewcdf’. Probesets were also associated to UniGene ID, official gene symbol 
and gene description, EntrezGene ID, RefSeq Transcript ID and OMIM ID. 
Differential expression tests were conducted using Limma package (64), using FDR method 
for multiple testing correction and setting significant threshold for adjusted p-value to 0.05.  
Functional enrichment tests. Pathway enrichment analysis of differentially expressed genes 
has been conducted using DAVID (Database for Annotation, Visualization and Integration 
Discovery, release 6.8 (65). Significant GO terms, PIR keywords, and KEGG and Reactome 
pathways have been selected considering p-values adjusted (Benjamini-Hochberg) at most 
0.05.
Collection of predicted and validated targets of miR-182 in MICOL-14h-tert and TC22. 
Target predictions for miR-182, consisting of predicted target gene transcripts (Ensembl)  and 
the corresponding prediction scores (Aggregate Pct, Cumulative Context ++ score and Total 
Cumulative Context ++), have been downloaded from TargetScanHuman (release 7.1 (66). 
Predicted target prioritization was based on the Total Cumulative Context ++ score. 
Experimentally validated miR-182 targets were downloaded from MirTarBase release 6.0 
(67). Two validation evidence strength categories, based on validation methods, were 
considered: strong (luciferase reporter assay, western blot, qPCR) and less strong (microarray, 
NGS, pSILAC). 




Among probesests significantly up-regulated after miR-182 silencing, those with average 
expression lower than 3 and a fold change lower or equal to 0.3 in both contrasts were filtered 
out. Selected up-regulated probests were matched with transcripts being predicted or validated 
miR-182 targets. 
The bioinformatic analysis of gene expression were performed in collaboration with Professor 
Bortoluzzi’s group (Department of Molecular Medicine, University of Padova, Italy).









Task 1:  miR-182 as possible biomarker of CRC progression 
ABSTRACT OF PUBLISHED RESULTS (see APPENDIX 1 for details) 
Regarding the first task, in my first year of PhD we published the attached paper (68,
Appendix 1) to confirm the involvement of miR-182 in CRC development and progression, 
and to investigate its possible role as prognostic biomarker. In particular, we analyzed in this 
study a total of 240 histopathological and 51 plasma samples. We observed by qRT-PCR a
progressive and significant over-expression of miR-182 along with the carcinogenesis cascade 
(Figure 1A). We then analyzed miR-182 dysregulation in CRC liver metastases, by 
investigating its expression levels in a series of stage IV CRCs. A significant overexpression 
of miR-182 was observed in primary CRCs and CRC liver metastases compared to normal 
tissues (Figure 1B) demonstrating that miR-182 up regulation starts at the beginning of colon 
carcinogenesis and is maintained in the metastatic process. We also investigated miR-182 
expression by ISH (In situ hybridization) in 5 cases of stage IV CRCs and a consistently 
significant overexpression was confirmed in paired primary tumors and CRC liver metastasis 
in comparison to normal colon mucosa (Figure 1C).
Figure 1: miR-182 is up-regulated during colon carcinogenesis. A. miR-182 expression was evaluated by 
qRT-PCR in FFPE samples of colon normal mucosa, tubular adenomas low-grade [LG] and high-grade [HG] 
intraepithelial neoplasia [IEN, formerly known as dysplasia] and CRCs. B. miR-182 expression was evaluated 
by qRT-PCR in matched surgical samples of normal colon mucosa, primary CRC and liver metastatis. C.
Representative ISH evaluation of miR-182 in matched tissue sections of normal colon, primary tumor and 
metastatic CRC (N= normal colon mucosa; K= primary CRC). The presence of miR-182 is shown by a grainy 
blue cytoplasmic stain; slides counterstained in fast red. (Original magnifications 10x and 20x). Significance 
(Student’s t test); *p<0.05; **p<0.01. nRQ, normalized Relative Quantity. Data were expressed as mean values
± SD.  




To further strengthen these results, we also evaluated the prognostic impact of miR-182 
expression on a large number of CRCs in The Cancer Genome Atlas (TCGA) CRC series 
(n=393). The miR-182 expression was significantly higher in CRCs presenting lymph node or 
liver metastases at diagnosis. Furthermore, in univariate analysis, and considering the median 
miR-182 value as a cut-off limit, miR-182 expression levels negatively correlated with the 
overall survival of patients (Mantel-Cox log-rank test, p=0.035). 
We then investigated whether the up-regulation of miR-182 expression in primary and 
metastatic CRC tissues could influence miR-182 concentration in the plasma of CRC patients. 
We demonstrated by qRT-PCR that plasma miR-182 concentrations were significantly higher 
in CRC patients than in healthy controls or patients with colic polyps at endoscopy (Figure 
2A). Considering tumor staging, miR-182 plasma expression level in both early and advanced 
CRC patients was significantly higher than in controls (Figure 2B). Finally, we analyzed 
paired pre- and post-operative samples from 11 CRC patients who underwent curative liver 
metastasectomy, and we observed that miR-182 plasma levels were significantly reduced one 
month after surgery (Figure 2C).  
Figure 2: miR-182 plasma levels are significantly elevated in CRC patients. A. miR-182 plasma levels were 
analyzed in 10 healthy volunteers, 10 patients with colic adenomas at endoscopy, 10 early stages and 10 late 
stages CRC patients. B. miR-182 plasma expression in advanced CRC patients and in early CRC patients. C.
Plasma miR-182 concentration before and after curative liver metastasectomy (p=0.020). Significance (Student’s 
t test); *p<0.05; **p<0.01. nRQ, normalized Relative Quantity. Data were expressed as mean values ± SD. 
These results indicate the potential of circulating miR-182 as a novel non-invasive blood 
based biomarker for CRC patients monitoring.  
This part of the PhD project was carried out in collaboration with Proff. M. Rugge’s group (Surgical Pathology 
and Cytopathology Unit, DIMED, University of Padova) and A. Scarpa’s group (Department of Diagnostics and 
Public Health, ARC-NET Research Center, University and Hospital Trust of Verona). 




Differentially expressed microRNAs in stage I-II colon cancer between tumor and 
matched normal colon mucosa.  
We evaluated by qRT-PCR in 48 localized colon cancer (stage I-II) the expression levels of 
five preselected miRNAs that resulted strongly modulated in primary advanced tumor (stage 
IV) versus normal colon mucosa in our previous work. The four up-regulated miRNA (miR-
18a, miR-21, miR-182 and miR-183) resulted involved in the same post-transcriptional 
network, while miR-139-5p (miR-139; sequence: UCUACAGUGCACGUGUCUCCAGU) 
was the most down-regulated. MiR-200c was confirmed to be the most stable normalizer and 
was used as a reference for the calculation of –ΔCt.  
Interestingly, our analysis confirmed that all of them are significantly regulated also in the 
early phases of the CRC tumor process. Specifically, miR-18a, miR-21, miR-182 and miR-
183 were strongly up-regulated (p << 0.001) in cancer tissue versus normal mucosa, whereas 
miR-139 was strongly down-regulated (p << 0.001), see Figure 1. This result is important 
because it shows that these five miRNAs accompany the CRC tumor process, from initial 
stages to advanced tumorigenesis. 
To then evaluate whether the modulations of these miRNAs were tumor-specific or the effect 
of tumor-associated inflammation, we checked their expression levels also in a situation of 
chronic inflammation. Specifically, we tested their expression levels in 10 patients affected by 
Ulcerative Colitis, a form of inflammatory bowel disease characterized by chronic and 
widespread inflammation of the colorectal mucosa. The comparison was performed analyzing 
the inflamed mucosa versus matched normal colon mucosa. 
Although with a limited sample size, our data support the fact that, among the up-regulated 
miRNAs, miR-182 and miR-183 are more specific of the tumor process, whereas miR-18a 
and miR-21 appear weakly modulated also in the chronic inflammatory process. Also the 
down-regulated miR-139 seems specific of the tumor process. MiR-18a and miR-21 appeared 
weakly up-regulated with p-value of 0.053 and 0.042, respectively, suggesting that the strong 
up-regulation of these two miRNAs in the tumor could be partially due to inflammation. On 
the contrary, miR-182, miR-183 and miR-139 were not significantly modulated in inflamed 
bowel tissue (Figure 2).




Figure 1: Boxplots of the distribution of –ΔCt values in tumor tissue versus matched normal mucosa for 
miR-18a, miR-21, miR-182, miR-183 and miR-139. Each dot represents a patient sample. –ΔCt values were 
calculated using miR-200c as a reference. Differences between cancer tissue (K) and matched normal mucosa 
(N) samples were analyzed using one-tailed Wilcoxon signed-rank sum test.  




Figure 2: Boxplots of the distribution of –ΔCt values in inflamed tissue versus matched normal mucosa for 
miR-18a, miR-21, miR-182, miR-183 and miR-139. Each dot represents a patient sample. –ΔCt values were 
calculated using RNU44 as a reference, which was proven to be more stable than miR-200c in these samples. 
Differences between inflamed bowel tissue (F) and matched normal mucosa (N) from patients affected by 
moderate ulcerative colitis were analyzed using one-tailed Wilcoxon signed-rank sum test. 




A coordinate deregulation of miRNAs as possible biomarkers of relapse 
To find possible biomarkers of relapse, the patients of the study were subdivided into a 
Recurrent group (R) and a Non-Recurrent group (NR) (see Table 1 in Materials and Methods 
section for details), and we tested on our data the miRNA ratio approach proposed by Boeri 
and colleagues (60).  
We thus calculated 10 ratios between the expression values of all possible miRNA pairs, both 
in the tumor tissue and in the adjacent normal mucosa, and assessed their capability to predict 
relapse through univariate logistic regression analysis. Complete results are reported in Table 
2 for both matched normal mucosa and tumor tissue. 
Three miRNA ratios, evaluated in the mucosa adjacent to tumor, were found to be significant 
predictors of relapse by 55 months from resection: miR-21/miR-183 (p=0.0011), miR-
18a/miR-182 (p=0.0053) and miR-18a/miR-183 (p=0.0099), see Figure 3. Corresponding 
areas under ROC curves (AUC) were 0.83 (miR-21/miR-183), 0.76 (miR-18a/miR-182) and 
0.78 (miR-18a/miR-183), see Figure 4. None of the miRNA ratios resulted significant in 
colon cancer tissue.  
Interestingly, the miRNA ratio approach was useful to show that not a single miRNA, but 
rather a coordinated alteration of four miRNAs (i.e. miR-21, miR-18a, miR-182 and miR-
183) from the same regulatory network, may be useful to predict recurrence after resection 
when evaluated in the tumor-adjacent mucosa and not in the tumor tissue. 
This result, apparently counterintuitive, is in line with previous findings reported in CRC (69)
and also in other tumors (70). Indeed, in a recent study (69) it was demonstrated that a 
number of genes related to the presence of the tumor were activated in adjacent mucosa of 
CRC patients. Moreover, these activated genes were enriched in transcription factors, 
indicating the existence of a transcriptional program driving the observed altered expression 
pattern in normal mucosa. At a higher level, we expect that also microRNAs are involved in 
regulating TFs and, in cascade, the genes activated in adjacent mucosa.   
Our results, if confirmed in an ample cohort of patients, may help to identify patients with 
localized CRC at high-risk of recurrence who would benefit most from adjuvant therapy. 




NORMAL MUCOSA TUMOR TISSUE
miR_ratio p-value AUC p-value AUC
miR-18a/miR-21 0.3084 0.58 0.40 0.51
miR-18a/miR-182 0.0053 0.76 0.46 0.56
miR-18a/miR-183 0.0100 0.78 0.46 0.49
miR-18a/miR-139 0.1178 0.60 0.51 0.61
miR-21/miR-182 0.0632 0.69 0.79 0.49
miR-21/miR-183 0.0011 0.83 0.99 0.53
miR-21/miR-139 0.1794 0.66 0.08 0.67
miR-182/miR-183 0.1752 0.56 0.65 0.62
miR-182/miR-139 0.7342 0.53 0.23 0.62
miR-183/miR-139 0.1919 0.58 0.20 0.63
Table 2. Evaluation of capability of predicting relapse of miRNA ratios in normal mucosa adjacent to 
tumor and in tumor tissue. A univariate logistic regression model was developed for each miRNA ratio to 
evaluate its capability to distinguish between patients who were relapsing by 55 months after bowel resection 
and those who did not, both in normal mucosa adjacent to tumor and in tumor tissue. The corresponding area 
under the ROC curve was calculated and reported in table as AUC. Three miRNA ratios resulted significant 
predictors of relapse (p<0.01 and AUC>0.75) in normal mucosa adjacent to tumor. 
Figure 3: Boxplots of the distribution of miR-21/miR-183, miR-18a/182 and miR-18a/183 ratios. The three 
miRNA ratios measured in the adjacent, morphologically normal, mucosa were predictive of relapse by 55 
months after bowel resection (p<0.01, in univariate logistic regression analysis). The panels show the 
distribution of miRNA ratio relative expression levels, indicated as 2-ΔCt, in CRC patients who relapsed by 55 
months after resection (R) and those who did not (NR). 




Figure 4: miR-21/miR-183, miR-18a/182 and miR-18a/183 ratios in normal mucosa adjacent to tumor 
predict the recurrence of colorectal cancer after bowel resection. ROC curves generated from univariate 
logistic regression models. Corresponding areas under ROC curves (AUC) were: miR-21/miR-183 (AUC=0.83), 
miR-18a/182 (AUC=0.76) and miR-18a/183 (AUC=0.78). 
This part of the PhD project was carried out in collaboration with Dott. A. Grassi (Oncology and Immunology 
Division, DiSCOG, University of Padova,). 
Manuscript submitted. 




Task 2: The inhibition of miR-182 increases the apoptosis and reduces 
tumor growth 
miR-182 is expressed at high levels in CRC cell lines 
Considering the set of four miRNAs that we have demonstrated to be associated with CRC 
tumorigenesis, miR-182 seems to be a key player. Indeed, in our previous work (54) we 
demonstrated that it has a central role in the post-transcriptional regulatory sub-network 
containing the most up-regulated miRNAs as it support, alone, the largest number of targets.
We evaluated the expression level of miR-182 in a panel of CRC cell lines by qRT-PCR, 
using a pool of normal colon mucosa samples as reference. We observed that miR-182
expression levels are significantly up-regulated, and specially CG-758 and TC22 showed the
highest expression levels between the cancer cell lines considered. In particular, the 
expression level of miR-182 is higher in TC22 compared to MICOL-14h-tert (Figure 5).
Figure 5: miR-182 expression levels in CRC cell lines compared to normal colon mucosa. Panel of CRC cell 
lines investigated by qRT-PCR for miR-182 expression level compared to normal colon mucosa. All cell lines 
show high levels of miR-182. Colon N, pool of normal colon mucosa sample. nRQ, normalized Relative 
Quantity. ** p<0.01. 




miR-182 silencing has no impact on Caco2 and HT29 cell lines 
In order to explore the functional role of miR-182 we initially chosen the well-known CRC
cell lines Caco2 and HT29, and we treated them with the anti- miR-182 or anti-miR-NC. We 
evaluated the inhibition of miR-182 expression levels by qRT-PCR at different time points 
after the treatment, and we observed a significant down-regulation of miR-182. In particular, 
the inhibition of miR-182 expression level in Caco2 was maintained at least until 72h post-
transfection, instead in HT29 the effect wears off after 48h, compared to NT and anti-miR-NC 
treated cells (Figure 6). 
Figure 6: mir-182 inhibition in Caco2 and HT29. The evaluation of the miR-182 expression levels was 
performed by real-time PCR at different time points after transfection. Data analysis was performed by ΔΔCt 
method, and the control groups (NT and anti-miR-NC treated cells) were used as sample references at each time 
point. Data were mean±SD of three independent tests. nRQ, normalized Relative Quantity. **p<0.01.
We carried out in vitro cell apoptosis and cell cycle assays at different time points after the 
treatment. These cell lines did not show significant differences about the percentage of 
apoptotic cells at 24, 48 and 72h after anti-miR-182 treatment, as demonstrated by Annexin V 
FITC/PI binding assay (Figure 7A). Likewise, also the cell cycle phases were not modify by 
miR-182 inhibition (Figure 7B). Therefore, we concluded that miR-182 did not induce a 
significant change in apoptotic levels and proliferation state in these cell lines.




Figure 7: Apoptotic and cell cycle assays in anti-miR-182 treated Caco2 and HT29 cells. A. Anti-miR-182
treatment did not show an apoptotic effect in Caco2 and HT29 cell lines. The percentage of cell population±SD 
shown is the mean of at least three independent experiments in triplicate. B. The cell cycle assay in Caco2 and 
HT29 cells was performed at 48 and 72h after treatment. The control groups (NT and anti-miR-NC treated cells) 
were used as references at each time point. 




Apoptosis-induced by inhibition of miR-182 in MICOL-14h-tert and TC22 
Based on different in vivo behavior we focused our attention on MICOL-14h-tert and TC22 cell 
lines as CRC model of tumor dormancy and its tumorigenic variant, respectively. We decided 
to evaluate in these cell lines the potential impact and functional role of miR-182 on tumor 
cell growth. 
To this aim, we treated the cells with anti-miR-182 or anti-miR-NC and we performed 
experiments to investigate cell apoptosis, cell cycle progression and cell migration. We 
evaluated the inhibition of miR-182 expression levels by qRT-PCR at different time points 
after the treatment, and we observed a significant down-regulation of miR-182 in both cell 
lines (Figure 8).  
Figure 8: mir-182 inhibition in MICOL-14h-tert and TC22 cells. The evaluation of the miR-182 level was 
performed by real-time PCR at 24, 48, and 72 h after transfection. Data analysis was performed by ΔΔCt 
method, and the control groups (NT and anti-miR-NC treated cells) were used as sample references at each time 
point. Data were mean±SD of three independent tests. nRQ, normalized Relative Quantity. **p<0.01.
MICOL-14h-tert showed a significant increase of cell apoptosis at 24h after miR-182 inhibition 
compared to NT or anti-miR-NC treated cells, which is maintained at least until 72h. TC22 
were not affected at 24h post-treatment, and a significant level of cell apoptosis was observed 
48h after treatment. In general, we observed that 72h after anti-miR-182 inhibition, a 
significant increase of cell apoptosis was detectable in both cell lines compared to the 




controls. In particular, the cell apoptosis due to inhibition of miR-182 was stronger in TC22 
compared to MICOL-14h-tert (Figure 9A).
To strengthen these evidences, we carried out Western blot experiments in whole cell lysates 
at 48h post-treatment to detect cleaved PARP and Caspase-3 proteins. Caspase-3 is one of the 
key executioners of apoptosis, as it is partially or totally responsible for the proteolytic 
cleavage of its main target PARP. This polymerase is important for cells to maintain their 
viability and its cleavage facilitates cellular disassembly and serves as a marker of cells 
undergoing apoptosis. We observed an over-expression of cleaved Caspase-3 in both cell 
lines after anti-miR-182 treatment, although significantly more evident in TC22. In 
agreement, total PARP decreased and cleaved PARP seems to be higher in tumorigenic 
variant after anti-miR-182 treatment, compared to MICOL-14h-tert (Figure 9B).
We performed the wound healing assay to evaluate whether miR-182 inhibition could have an 
effect on cell migration. The scratch assay is a common method to track migration of 
individual cells at the leading edge of the gap. MICOL-14h-tert and TC22 were seeded and 
treated with anti-miR-182 or control, and a scratch was applied after 24h directly on the 
monolayer with a sterile pipette tip (T0). The cell ability to move and fill again the scratch 
was evaluated at different time points. As shown in Figure 9C, 18h after the scratch (42h after 
miR-182 inhibition) MICOL-14h-tert closed the gap. At the same time point, TC22 cell 
proliferation was not evaluable because of the strong pro-apoptotic effect of miR-182 
inhibition. Indeed, a high amount of cells appear detached from the well plate modifying their 
morphology and appearing smaller and rounded (Figure 9C).  




Figure 9. Anti-miR-182 treatment induced apoptosis in MICOL-14h-tert and TC22 cell lines. A. Anti-miR-
182 increases the sensitivity of cells to apoptosis as determined by Annexin V/PI staining using the Annexin-V-
FLUOS kit. The fold change±SD shown is the mean of at least three independent experiments in triplicate. B.
Western blot analysis of CRC cell lines transfected with miR-182 inhibitor using anti-caspase 3 and anti-PARP 
antibodies show increased level of marker proteins of apoptosis. Β-actin was used as a loading control. 
Photograph is representative of three independent experiments. C. Representative images depicting a cell 
migration assay performed in anti-miR-182 treated cells. At right MICOL-14h-tert have restored the monolayer 
homogeneously after 18h from the scratch (42h post-treatment), instead on the left, TC22 were detached from 
the plate due to diminished cell vitality. The control groups (NT and anti-miR-NC treated cells) were used as 
references at each time point. *p<0.05, **p<0.01. 




miR-182 partially influences the cell cycle progression in the tumorigenic variant TC22 
We also assessed in MICOL-14h-tert and TC22 whether miR-182 is involved in cell cycle 
progression. Our findings showed that miR-182 partially influences also the cell cycle 
progression of TC22. Indeed, 48h after anti-miR-182 treatment, the proportion of cells in 
G0/G1 phase was weakly increased while the proportion of cells in S and G2 phases was 
decreased, compared to controls. MICOL-14h-tert, instead, did not present variations of cell 
cycle phases after anti-miR-182 treatment (Figure 10).
Hence, miR-182 inhibition seems not to affect the cell cycle progression in MICOL-14h-tert
and only a weakly decrease of cell proliferation was detectable in the tumorigenic variant 
TC22. 
Figura 10. Anti-miR-182 weakly decreased cell cycle progression of TC22 cells. The cell cycle assay in 
MICOL-14h-tert and TC22 cells was performed at 48 and 72h after the treatment. The control groups (NT and 
anti-miR-NC treated cells) were used as references at each time point. 




miR-183 is modulated by inhibition of miR-182, instead anti-miR-183 treatment only 
partially affected the miR-182 expression level and apoptosis
We previously demonstrated that miR-182 is related to other important up-regulated miRNAs 
in a transcriptional regulatory network. In particular, miR-182 with miR-183 share several 
common target genes (54). Furthermore, these miRNAs were described as members of the 
miR-183 family and polycistronic miR-183-96-182 cluster (71). Indeed, they were transcribed 
in the same direction from physically adjacent miRNA genes, are characterized by sequence 
homology and could function synergistically. Starting from these premises, we investigated 
by qRT-PCR whether the inhibition of miR-182 in MICOL-14h-tert and TC22 cells could 
affect the expression level of miR-183, and viceversa. We observed that the anti-miR-182 
treatment also induced a significant down-regulation of miR-183 expression level compared 
to controls at each time point considered in both cell lines (Figure 11A). Instead, the 
inhibition of miR-183 also partially influenced the miR-182 expression level. In particular, 
MICOL-14h-tert showed a decrease of miR-182 only at 72h after the treatment, while TC22 
cells presented a significant miR-182 down-regulation after 24h post-treatment (Figure 11B).  




Figure 11. Anti-miR-182 treatment significantly influences the miR-183 expression level, instead miR-183
inhibition partially reduced miR-182 expression level. A. The evaluation of miR-183 expression level 
following the miR-182 inhibition was performed in MICOL-14h-tert and TC22 cells by qRT-PCR at 24, 48, and 
72h after treatment. B. The evaluation of miR-182 expression level after the anti-miR-183 treatment was 
performed in both cell lines by qRT-PCR at 24, 48, and 72h after treatment. Data were analyzed by ΔΔCt 
method, and the control groups (NT and anti-miR-NC) were used as references at each time point considered.
Data were mean±SD of three independent tests. nRQ, normalized Relative Quantity. *p<0.05, **p<0.01. 
In order to clarify whether the pro-apoptotic effects were a direct consequence of miR-182 
inhibition or could be also ascribed to miR-183 or both, we evaluated the effect of anti-miR-
183 treatment on cell apoptosis. We observed that the anti-miR-183 treatment did not induce 
significant variation until 48h in both cell lines, compared to controls. Starting from 72h we 
measured a substantial apoptotic effect in MICOL-14h-tert, and more significant in tumorigenic 
variant TC22 (Figure 12). Interestingly, the cellular apoptosis in MICOL-14h-tert was 
enhanced only at 72h after the anti-miR-183 treatment (Figure 12), in agreement with the 
down-regulation of miR-182 due to miR-183 inhibition (Figure 11B). 
In addition, we investigated the consequence of the co-inhibition of miR-182 and miR-183, 
and we observed the same results obtained with the inhibition of miR-182 alone (data not 
shown).
Figure 12: Anti-miR-183 induced apoptosis 72h after the treatment in both cell lines. Inhibition of miR-183
increases the sensitivity of cells to apoptosis only after 72h as determined by Annexin V/PI staining. The 
percentage cell population±SD shown is the mean of at least three independent experiments in triplicate. The 
control groups (NT and anti-miR-NC treated cells) were used as references at each time point. *p<0.05, 
**p<0.01. 




miR-182 inhibition in TC22 xenografts reduces the in vivo tumor growth 
With the aim to evaluate the effect of anti-miR-182 treatment in vivo, we injected 
subcutaneously TC22 cell lines after anti-miR-182 or anti-miR-NC treatment in NOD/SCID 
mice. Initially, we verified by qRT-PCR how long the transient inhibition of miR-182 was 
maintained in TC22 cells, and we observed that the miRNA was down-regulated until at least 
1 week after transfection (Figure 13).  
We injected anti-miR-182 treated cells at 24h after in vitro transient transfection, and 1 week 
later we performed also an in vivo intra-tumoral anti-miR-182 injection using 
Invivofectamine. The resulting tumors were inspected periodically and measured by caliper.
All of the mice survived until the experimental end point. 
Figure 13. Experimental workflow for injection of TC22 cells with miR-182 inhibition in mice. TC22 cell 
lines was treated with anti-miR-182 or anti-miR-NC, and after 24h they were s.c. injected in NOD/SCID mice. 
After a week we performed in mice an intratumoral injection with in vivo ready anti-miR-182 and 
Invivofectamine. We also demonstrated by qRT-PCR that, after a week from transfection, TC22 maintained the 
in vitro miR-182 inhibition. After 3and 5 weeks from the injection of TC22 treated cells the tumor sizes were 
significantly reduced by miR-182 inhibition. The control group (anti-miR-NC treated cells) was used as 
references at each time point. 




We found that anti-miR-NC controls developed growing tumors invariably higher compared 
to anti-miR-182 treated cells (Figure 14). Interestingly, we observed that miR-182 inhibition 
significantly reduced tumor size after 3 weeks from the injection (p-value=1,56x10-5). 5
weeks after tumor cell injection, the tumor mass were still different, although the differences 
were less significant (p=0.018) (Figure 14A). Subsequently we performed H&E staining on 
the samples obtained from the tumor mass to analyze the possible histological and 
morphological changes induced by miR-182 inhibition. In particular, we observed that the 
tumor mass obtained with both NT and anti-miR-NC treated cells was characterized by the 
aspect of moderately to poorly differentiated adenocarcinoma, with bulky appearance, 
trabecular-solid pattern, minimal fibrosis and pushing borders. The anti-miR-182 treated 
TC22 cells showed to grow mainly as moderately differentiated adenocarcinoma, with mild 
fibrosis within (Figure 14B, Table 3). The histological aspect of anti-miR-182 resulting 
tumors reminds the one of treated CRC, that is fibrotic and with atrophic features. None 
presents conspicuous necrosis, but isolated necrotic foci and minimal leukocyte infiltration 
are detectable in all three groups. Finally, we demonstrated that anti-miR-182 treatment 
significantly reduced tumor growth and modified the tumor cell morphology in vivo. 
 




Figure 14. miR-182 inhibition in TC22 xenografts reduced the growth and modified morphological 
features of the tumor. A. Box plot distribution of tumor mass volume resulting in TC22 xenografts 5 weeks 
after tumor cell injection with anti-miR-182 or anti-miR-NC. miR-182 silencing leads to observe smaller tumors 
in treated mice compared to controls. Center lines show the medians; box limits indicate the 25th and 75th 
percentiles as determined by R software. Data points are plotted as open circles. n = 8, 10 sample points. B.
H&E staining of tumor sections. NT and anti-miR-NC tumors presented the same histological and 
morphological pattern compared the anti-miR-182 treated tumor mass in vivo, in which the adenocarcinoma was 
moderately differentiated with mild fibrosis. Magnification 10X and 20X. The control groups (NT and anti-miR-
NC treated cells) were used as references at each time point. 




One of the main histological and morphological aspects that may be considered in the 
dynamic development of colorectal carcinoma, besides the grading of de-differentiation and 
growth pattern, is the mitotic index. This is defined as the ratio between the number of cells in 
a population undergoing mitosis to the number of cells in a population not undergoing 
mitosis, thus it measures cellular proliferation. As detailed in Table 3 we evaluated the mitotic 
index of the tumor mass, and we observed that in controls generally it was higher compared to 
those from anti-miR-182 treated TC22 cells. 
Table 3: Mitotic index and grading were lower in tumor mass from anti-miR-182 treated TC22 than 
controls. Inhibition of miR-182 decrease the mitotic index of the tumor cells. Controls grew as G2/G3 or G3 
adenocarcinomas, while anti-miR-182 treated tumor mass grew mainly as moderately differentiated 
adenocarcinoma (G2 and G2/G3). The control groups (NT and anti-miR-NC treated cells) were used as 
references. 
The in vivo experiments were performed in collaboration with Dott. M. Curtarello of the S. Indraccolo’s group 
(Oncology and Immunology Division, DiSCOG, University of Padova).
The morphological and histological evaluations were performed in collaboration with Dott. L. Albertoni of the 
Professor Rugge’s group (Surgical Pathology and Cytopathology Unit, DIMED, University of Padova).




































Differentially expressed transcripts modulated by miR-182 in MICOL-14h-tert and TC22 
To investigate the mRNA expression profile and to explain the involvement of miR-182 in 
molecular pathways relevant to cancer we carried out Primeview Array in MICOL-14h-tert and 
TC22 after anti-miR-182 treatment. We analyzed total RNA of the cells after anti-miR-182 
and anti-miR-NC treatment and for each condition we obtained four replicates for a total of 
16 samples. We acquired expression profiles of 49,293 probesets, corresponding to 41,532 
transcripts and to 19,942 genes.  
In Figure 15 is described the dataset, providing the box-plots of log-intensity distributions in 
considered samples after normalization (Figure 15A) and descriptive unsupervised analyses, 
as Principal Component Analysis (PCA; Figure 15B) and pairwise sample correlation based 
on transcript expression profiles (Figure 15C). Both PCA and sample correlations showed 
that, as expected, samples separated first for cell line and then by treatment underlying the 
effect on expression profiles of miR-182 inhibition. 
Figure 15. Descriptive analyses of gene expression profiles in MICOL-14h-tert and TC22 after anti-miR-182 
or anti-miR-NC treatment. A. Boxplot of intensity values distribution per samples after RMA normalization; 
unsupervised analyses depicting sample relationships, considering expression profiles of all probesets and 
transcripts represented in Primeview arrays, are reported in B. PCA analysis and C. pair-wise sample correlation 
plot. M14, MICOL-14h-tert; a182, anti-miR-182; aNC, anti-miR-NC. 




The heatmap in Supplementary Figure 1 shows the cluster analysis and the expression 
profiles of a subset of 12,323 transcripts (25% of the total) selected according to expression 
level and variability across the total of samples. Differentially expressed probesets with 
significantly variable expression after miR-182 inhibition were detected in both cell lines 
(Table 4). The impact of anti-miR-182 on gene expression was more important in the TC22 
cells, where 1,878 probesets, corresponding to 3,472 transcripts and 1,382 genes, resulted 
significantly modulated. In MICOL-14h-tert cells we detected 312 differentially expressed 
probests (669 and 243 transcripts and genes, respectively). The anti-miR-NC treated cells 






Up-regulated 228 487 172
Down-regulated 84 182 70
Total 312 669 243
TC22
a182 vs aNC
Up-regulated 772 1342 574
Down-regulated 1106 2130 816
Total 1878 3472 1382
Table 4: Differential expression after miR-182 inhibition in MICOL-14h-tert and TC22 cell lines. For each 
cell type, the total number of significantly differentially expressed probesets (adjusted p-value < 0.05) and the 
corresponding number of unique transcripts and genes is indicated; counts of up- and down-regulated elements 
are also indicated separately. a182, anti-miR-182; aNC, anti-miR-NC. 
The Figure 16A shows the heatmap of differentially expressed probesets in MICOL-14h-tert
cells, corresponding to 487 and 182 transcripts after miR-182 inhibition. Symmetrically, the 
heatmap in Figure 16B displays the expression profile variations in TC22 cells after miR-182 
treatment, showing also that a higher number of down- than up-regulated probesets were 
detected, corresponding to 2,130 down- and 1,342 up-regulated transcripts. 




Figure 16. Heatmaps of expression profiles of probesets differentially expressed after miR-182 inhibition. 
A. and B. showed 3,472 and 669 differentially expressed probesets detected in TC22 and MICOL-14h-tert cell 
lines, respectively. a182, anti-miR-182; aNC, anti-miR-NC. 




Notably, 158 genes were associated to probesets and transcripts differentially expressed after 
miR-182 inhibition in both cell lines. The large majority (153) of common genes deregulated 
after the treatment changed in the same direction in the two cell lines, with 103 and 50 that
were respectively up- and down-regulated.  
Functional Gene Ontology (GO) terms and KEGG and Reactome pathways significantly 
enriched among differentially expressed genes were reported in Supplementary Table 2.
According to TarBase data, 12 genes (ATF1, ANKRD36, BRWD1, DDAH1, FAM193A,
FLOT1, NR3C1, PNISR, QSER1, RBM12, SESN2, and TNRC6A) that we found 
significantly up-regulated after miR-182 inhibition were already validated as miR-182 target 
genes. Among them, ATF1 and FLOT1 were the first target validated with strong evidence 
based on luciferase reported assays and other methods. In our data, ATF1 was up-regulated in 
both cell lines with a fold change of at most 0.41. FLOT1 resulted up-regulated only in TC22 
cells with a fold change at most 0.40. (Supplementary Table 3).
Next, we aimed to identify new putative direct miR-182 targets, which were expected to be 
up-regulated after the miRNA inhibition. To this purpose, we selected 1,086 probesets 
showing more marked expression variation in terms of average expression and fold change 
(see Methods), corresponding to 1,825 transcripts from 759 genes. We then focused on 492 of 
these selected up-regulated transcripts (from 218 genes, corresponding to 323 probesets) that 
were putative miR-182 targets, since they carried one or more miR-182 target sites according 
to TargetScan predictions and passed our score- and expression-based filtering 
(Supplementary Table 4). Based on these criteria of selection, the availability of transcript 
assays and the biological role we validated by qRT-PCR four putative targets (HIST1HBH, 
NABP1, RND3, TRIO) (Figure 17).
The bioinformatics analysis of gene expression were performed in collaboration with Professor Bortoluzzi’s 
group (Department of Molecular Medicine, University of Padova).




Figure 17. miR-182 transcript targets validation. A. Description of validated target gene transcripts and 
logFC up-regulation in MICOL-14h-tert and TC22 cell lines after miR-182 inhibition. B. The evaluation of the 
transcript expression levels was performed by real-time PCR in cell lines and, for NABP1 also in sample tissues. 
Data analysis was performed by ΔΔCt method, and the control groups (NT and anti-miR-NC treated cells) were 
used as sample references in cell lines. Normal colon mucosa (N) was used as reference for primary tumor tissue 
(T). Data were mean±SD of three independent tests. nRQ, normalized Relative Quantity. *p<0.05 **p<0.01.
Manuscript in preparation.





Colorectal cancer is the third most common cancer and the third leading cause of cancer death 
in men and women (1). Adjuvant chemotherapy is usually reserved to node-positive (TNM 
stage III) patients, whereas no further treatment is recommended for node-negative (TNM 
stage I and II) patients after surgical resection. Actually, within five years from surgery, up to 
20% of node-negative patients develop recurrence and the identification of biomarkers able to 
characterize a node-negative population at highest risk of recurrence, who could benefit more 
of adjuvant chemotherapy, is still elusive. 
However, metastatic spread remains the ultimate cause of cancer-related death in most CRC 
cases, and 20-25% of patients present metastatic disease at diagnosis. Only about 70% of 
stage III CRC cases with regional lymph node metastasis are curable by surgery combined 
with adjuvant chemotherapy. Metastatic disease (stage IV), despite improved survival due to 
recent advances in chemotherapy, is usually incurable (74, 75). Therefore, it is of critical 
importance to understand the molecular alterations involved in CRC development and 
progression, and identify diagnostic and prognostic biomarkers for improving CRC patients’ 
survival (23, 76).  
Using a large dataset of CRC miRNA and gene expression profiles, we previously described 
(54) the interplay of miRNA groups in regulating gene expression, which in turn affects 
modulated pathways that are important for tumor development. The data we obtained 
demonstrate that miR-182 could contribute to colorectal cancer tumorigenesis and 
progression.  
In the attached paper published in my first year of PhD (68, Appendix 1) we confirmed that 
miR-182 is significantly up-regulated during colon carcinogenesis cascade and metastasis, 
and is associated to prognosis of CRC patients. The miR-182 prognostic impact is also 
supported by our elaboration of data from TCGA CRC cohort showing higher miR-182 
expression in more advanced stages of CRC, and shorter survival in patients with high miR-
182 expression levels. Due to the stability of circulating miRNAs as well as the role of 
miRNA dysregulation at different stages of carcinogenesis, they have the potential to serve as 
very promising non-invasive biomarkers for different types of human cancers (72). Therefore, 
we demonstrated that also plasma miR-182 levels are significantly higher in CRC patients 
than in healthy controls and were significantly reduced in post-operative samples after radical 
hepatic metastasectomy, compared to pre-operative samples. These results showed that miR-




182 up-regulation starts at the beginning of colon carcinogenesis and is maintained in the 
metastatic process. Our findings also indicated that the evaluation of circulating miR-182
levels could be a promising approach to improve the repertoire of non-invasive blood based 
biomarkers for CRC monitoring and screening. 
In the following submitted manuscript, we then analyzed an independent series of patients 
with localized CRC (stage I/II, N0 M0) subdivided in Recurrent group and Non-Recurrent 
group. In particular, we explored the efficacy of a set of 5 miRNAs, already known to be 
involved in CRC progression, as biomarkers of relapse after bowel resection. Our analysis 
confirmed that the panel of selected miRNAs were strongly differentially expressed also in 
the early phases of the CRC tumor process, suggesting a promoting role already in the initial 
steps of colon carcinogenesis. Specifically, miR-18a, miR-21, miR-182 and miR-183 were 
strongly up-regulated in cancer tissue vs. normal colon mucosa, whereas miR-139 was 
strongly down-regulated. This finding extended to stage I-II CRC the results obtained in our 
previous work in stage IV CRC (54), showing that these five miRNAs accompany the CRC 
tumor process, from initial stages to advanced tumorigenesis. Moreover, our data indicated 
that the modulations of miR-182, miR-183 and miR-139 are more specific of the tumor 
process. MiR-18a and miR-21, instead, appear weakly up-regulated also in inflamed bowel 
tissue, thus suggesting that the strong up-regulation of these two miRNAs in the tumor could 
be partially related to inflammation. We thus hypothesized that these miRNAs, that 
accompany the tumorigenesis process, were present also in the pre-neoplastic, 
morphologically normal, mucosa adjacent to the tumor and that could be tested as possible 
predictors of relapse. Our results suggested that not a single miRNA, but rather a coordinated 
alteration of four miRNAs (i.e. miR-21, miR-18a, miR-182 and miR-183) from the same 
post-transcriptional network, may be useful to predict recurrence after resection, when 
evaluate in the normal mucosa adjacent to tumor. Furthermore, the miRNA ratio approach 
described in the present study may be transported for the evaluation of these modulated 
miRNAs into the plasma tissue and applied on a large-scale, as it requires measuring only 
four miRNAs and overcomes the need for a normalizer RNA. Interestingly, the miRNA ratios 
resulted to be predictive markers when evaluated in the adjacent, morphologically normal, 
mucosa and not in the tumor tissue. This result, apparently counterintuitive, is in line with 
previous findings reported in CRC (69) and also in other tumors (70, 77). Indeed, it is 
emerging with increasing evidence that the crosstalk between tumor and microenvironment 
could affect the adjacent mucosa and that also this tissue may be informative. In a recent 




study, Sanz-Pamplona et al. (69) demonstrated that a number of genes related to the presence 
of the tumor were activated in adjacent mucosa of CRC patients. Moreover, these activated 
genes were enriched in transcription factors (TFs), indicating the existence of a transcriptional 
program driving the observed altered expression pattern in normal mucosa. At a higher level, 
we expected that also miRNAs are involved in regulating TFs and, in cascade, the genes 
activated in adjacent mucosa. MiRNA expression in adjacent mucosa could be modulated in 
response to signals produced by the tumor to establish a tumor-microenvironment crosstalk 
advantageous for neoplastic transformation process, or it could be an indicator of 
microenvironment remodeling associated with the local progression of cancer. In this study 
we highlighted the importance of its investigation also for the presence of potential 
biomarkers of tumor relapse. 
The main limitation of our analyses is the restricted samples size, which could affects the 
statistical evaluation of miRNA expression levels and their relationships to 
clinicopathological variables. Nevertheless, this first part of the study has several important 
clinical implications. First, the specific involvement of miR-182 in CRCs indicates its 
potential to be developed into a potential non-invasive marker for these patients. Secondly, 
miR-182 in combination with other miRNAs could be a possible prognostic biomarker for the 
monitoring of relapse in localized CRC patients. These results, if confirmed in an ample 
cohort of patients, may help to identify patients at high-risk of recurrence who would benefit 
most from adjuvant therapy. 
To gain insights in the functional role played by miR-182 in the tumorigenesis, in a parallel 
set of experiments we investigated the effects of miR-182 inhibition in CRC cell lines. We 
first evaluated Caco2 and HT29 cell lines, in which we did not observe an impact on cell 
apoptosis. Probably in these CRC cell lines, miR-182 acts exploiting other molecular 
mechanisms that we have not investigated and highlighted. However, these cell lines as well-
known cancer cell lines are easy to culture and have limitless growth potential. So, they could 
be maintained in vitro for prolonged periods, and consequently can change genetically over 
multiple passages partially losing the feature to be representatives of the cancers from which 
they were derived (78). Thereafter, we focused on other two colorectal cancer cell lines as in
vitro models: MICOL-14h-tert (an in vivo non-tumorigenic cell line derived from a lymph node 
metastasis of rectal cancer) and its in vivo tumorigenic variant TC22. Interestingly, as 
reported by Dalerba P. et al (55), in MICOL-14h-tert the set of detected mutations 




corresponded to that of the original tumor tissue proving that the cell culture was 
representative of the tumor in vivo cell population.  
By analyzing the expression levels of miR-182, we observed that it was higher in TC22 
compared to MICOL-14h-tert, suggesting a role of this miRNA in tumor aggressiveness. We 
demonstrated that, a significant increase of cell apoptosis was stronger in TC22 compared to 
MICOL-14h-tert after miR-182 inhibition. Furthermore, a partially modulation of cell cycle 
progression in TC22 due to anti-miR-182 treatment, was detectable. We observed also a 
down-regulation of miR-183 after the inhibition of miR-182, in both cell lines. To further 
deepen whether the pro-apoptotic effects were a direct consequence of miR-182 inhibition or 
could be also ascribed to miR-183 or both, we also evaluated the effect of miR-183 inhibition 
on miR-182 expression level and cell apoptosis. We concluded that in both cell lines the 
effect of miR-183 inhibition was lower and delayed compared to that induced by anti-miR-
182 treatment, and that miR-183 only partially affected the miR-182 expression level and 
apoptosis. We also investigated the consequence of the co-inhibition of miR-182 and miR-
183 together, and we observed the same results obtained with the inhibition of miR-182 alone. 
These results highlighted the hypothesis that the main regulator of cell viability in these 
cancer cell lines is miR-182 rather than miR-183. 
Interestingly, the in vivo injection of anti-miR-182 treated TC22 cells showed a significant 
reduction of tumor growth and a modified morphology features, that appeared with less 
aggressive properties. These data showed that regulation of miR-182 expression levels in 
TC22 xenografts markedly contributed to modulate CRC cell proliferation and tumorigenic 
potential.
The cancer is a limited number of "mission critical" events that propel the tumor cell into 
expansion and uncontrolled invasion. One of these is cell proliferation, which, together with 
the compensatory suppression of apoptosis, provides a minimal 'platform' necessary to 
support neoplastic progression (79). The evasion of apoptosis, which is critical for tumor 
growth and progression (80), could be a mechanism central to oncogenesis in colon cancer 
exhibiting increase of miR-182 expression level, permitting survival of cells with damaged 
DNA. Indeed, miR-182 inhibition caused a significant increase in the level of both activated 
caspase-3 and PARP, indicators of irreversible damage to the integrity of cell and genome, 
with a resultant increase in apoptotic activity (81). The results were also confirmed by 
bioinformatics analysis, in which the “positive regulation of apoptotic process” emerged as 
one of the most GO BP (Biological Process) significantly modulated from miR-182 inhibition 




in both cell lines (Supplementary Table 2). In order to identify the regulatory molecular 
pathways by which this miRNA could act we also investigated the predicted target genes of 
miR-182. We partially validated several putative target transcripts, and in particular 
HIST1H2BH, NABP1, RND3 and TRIO, based on the availability of the experimentally 
assays and biological role. The HIST1H2BH gene is part of the histone family that are 
responsible for the nucleosome structure of the chromosomal fiber, and play a central role in 
DNA repair and chromosomal stability. Other components of core histones resulted 
modulated by miR-182 inhibition. Likewise, NABP1, an important paralog of NABP2, is a 
single-stranded DNA-binding protein (SSB) that promote the repair of DNA damage and 
G2/M checkpoint, and it is involved in the maintenance of genomic stability (82). Recently, 
Zhang F. et al. identified also INTS6, a gene modulated by miR-182 inhibition, as a major 
subunit of the core human SSB complex, and they demonstrated that INTS6 relocates to the 
DNA damage sites (83). The function of RND3, an atypical member of Rho family, is 
complex. It has been demonstrated to induce apoptosis in prostate cancer, esophageal 
squamous carcinoma and glioblastoma cell lines (84). TRIO encodes a large protein that 
functions as GDP to GTP exchange factor and that promotes the reorganization of the actin 
cytoskeleton, thereby playing a role in cell migration and growth (85). 
To further deepen and confirm the role of miR-182 in CRC we are now testing the direct 
interaction of miR-182 with selected target genes using: the 3’UTR Lenti-reporter-Luc Vector 
in the Luciferase assay; in vitro over-expression of target gene by plasmid transfection and 
evaluation of functional effects; evaluation of protein expression levels of putative miR-182 
target genes involved in functional networks. 
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Supplementary Table 1: STR profiling of CRC cell lines. Description and comparation of CRC cell lines 
using a set of 16 STR markers. In the right, MICOL14h-tert and TC22 show the same STR profile.  NA, not 
analyzed markers 
Caco2 HT29 MICOL14h-tert TC22
D3S1358 NA NA 15 15
TH01 6 6-9 6-7 6-7
D21S11 30 29-30 29 29
D18S51 12 13-9.2 14 14
Penta E NA NA 9 9
D5S818 12-13 11-12 13 13
D13S317 13 11-12 12 12
D7S820 11-12 10 8-10 8-10
D16S539 12-13 11-12 9-13 9-13
CSF1PO 11 11-12 11 11
Penta D NA NA 13 13
AMEL X X X X
vWA 16-18 17-19 15-16 15-16
D8S1179 12 10-16 11 11
TPOX 9-11 8-9 8-13 8-13











Supplementary Figure 1. Unsupervised cluster analysis and expression profiles. The heatmap showed 
sample clustering and expression profiles of a subset of 12,323 transcripts selected according to expression level 
and variability across the 16 considered total samples (average expression value and coefficient of variation > 
median). M14, MICOL-14h-tert; a182, anti-miR-182; aNC, anti-miR-NC.
 




Supplementary Table 2. Gene Ontology (GO) functional terms, KEGG and Reactome pathways 
significantly enriched considering genes differentially expressed after miR-182 inhibition. Enriched terms, 
involved genes and fold-enrichment are showed separately for each cell line and considering only genes resulting 
differentially expressed after miR-182 inhibition in both cell line. BP, Biological Process; CC, Cellular 




















ITGB3BP, EID3, SRSF10, EID2B, PPHLN1, 
ZNF557, SPTY2D1, NR3C1, ZNF638, ZNF655, 
ZNF165, ZFP36L1, SRRT, SFSWAP, ZNF181, 








ITGB3BP, HIF1A, SQSTM1, TRIO, GADD45B, 






ITGB3BP, TUBB2A, EID2B, CLK1, HIST2H4A, 
TCEAL1, CAMKK2, NFATC2IP, FUBP1, SFSWAP, 
CCNE1, ZNF181, BLZF1, CLK4, ANKRD11, 
NSMCE2, AKIRIN1, IP6K2, ZNF101, TIGD1, RELB, 
CCNL1, NABP1, HIF1A, MSANTD4, CUX1, 
GADD45B, GADD45A, SRSF10, SLF2, ZNF557,
NR3C1, ZNF655, PXK, SESN2, TSPYL4, 
ZFP36L1, SFR1, VRK2, ZNF226, HIST1H4E, 
THAP1, TCF3, ZNF267, FKTN, TKT, ZNF165, 





ITGB3BP, EID3, SRSF10, NR3C1, ZNF638,
HIST2H4A, TCEAL1, FUBP1, CCNE1, SRRT, 
BLZF1, SQSTM1, ANKRD11, HIST1H4E, 
NSMCE2, AKIRIN1, TCF3, AKT3, IP6K2, NQO2, 
PPP4R3B, PPHLN1, RELB, TKT, TRNT1, NABP1, 
CDKN1A, ATF3, HIF1A, SMARCC1, MAPK9, 






ITGB3BP, TUBB2A, CLK1, HIST2H4A, LATS1, 
RSRC2, FUBP1, SFSWAP, CCNE1, BLZF1, CLK4, 
ARL14, RABGEF1, NSMCE2, AKIRIN1, AKT3, 
ZNF101, NQO2, IP6K2, RAP2A, TTC32, RELB, 
CCNL1, RBKS, CCT6A, C8ORF44-SGK3, MRM1, 
BCL2L11, NABP1, HIF1A, NUCB2, USO1, MAPK9, 
G0S2, MAPRE2, GADD45B, SCAF8, GADD45A, 
EID3, SRSF10, SLC38A9, SNX5, CALD1, SLF2, 
RPS15A, FAM122A, FKBP1A, NR3C1, C6ORF226, 
ZNF655, TSPYL4, PPCDC, SESN2, ZFC3H1, 
ZFP36L1, SRRT, SFR1, VRK2, C1ORF50, KLC1, 
SQSTM1, HIST1H4E, LETMD1, THAP1, TCF3,
INPP5A, PHLDA1, CCNB1IP1, RBM12B, PPHLN1, 
ASXL1, TRIO, TKT, RCAN3, VAV2, SGTB, ATG3, 
RPL28, ZNF165, PPIF, CDKN1A, C1ORF116, 





CDKN1A, MAPK9, GADD45B, C8ORF44-SGK3, 
GADD45A, AKT3, BCL2L11 7 8.31 0.0185


















ITGB3BP, EID3, SRSF10, EID2B, ZNF558, 
ZNF557, NR3C1, ZNF638, ZNF655, NOCT, 
ZFP36L1, SRRT, SFSWAP, ZNF181, ZNF226, 
THAP1, TCF3, ZNF267, ZNF101, L3MBTL4, 
ZBTB21, PPHLN1, SPTY2D1, ARNTL, DDIT3, 








ITGB3BP, ABR, HIF1A, SQSTM1, MTCH1, TRIO, 







ITGB3BP, HIST4H4, HIST2H2BF, HIST1H3A, 










HIST4H4, HIST1H3A, HIST1H4E, HIST2H4A, 








HIST4H4, HIST1H4E, NSMCE2, HIST2H4A, 






HIST4H4, HIST1H3A, HIST1H4E, HIST2H4A, 







ITGB3BP, HIST4H4, HIST1H4E, HIST2H4A, 





HIST4H4, HIST1H3A, HIST1H4E, HIST2H4A, 






HIST4H4, HIST1H3A, HIST1H4E, HIST2H4A, 
HIST1H4I, HIST1H4J 6 13.93 8.57E-03
GO BP GO:0032776~
DNA 
HIST4H4, HIST1H3A, HIST1H4E, HIST2H4A, 
HIST1H4I, HIST1H4J 6 15.57 6.90E-03













HIST4H4, HIST1H3A, HIST1H4E, HIST2H4A, 








HIST4H4, HIST1H4E, HIST2H4A, HIST1H4I, 






HIST4H4, HIST1H4E, HIST2H4A, HIST1H4I, 








HIST4H4, HIST1H4E, HIST2H4A, HIST1H4I, 




ITGB3BP, CYP24A1, HIST4H4, EID2B, TUBB2A, 
RBM3, CLK1, HIST2H4A, TCEAL1, DGCR14, 
NOCT, CAMKK2, FUBP1, NFATC2IP, SFSWAP, 
CCNE1, ZNF181, BLZF1, CLK4, ANKRD11, 
C8ORF4, NSMCE2, SMOX, NFIL3, AKIRIN1, 
ZNF101, IP6K2, L3MBTL4, ZBTB21, TIGD1, RELB, 
CCNL1, ARNTL, MXD3, DDIT3, NABP1, HIF1A, 
HIST2H2BF, MSANTD4, GADD45B, CUX1, 
GADD45A, CAMTA2, ZNF552, SRSF10, ZNF558, 
ZNF557, SLF2, TRA2A, TRIB3, NR3C1, ZNF655, 
PXK, TSPYL4, ZNF177, SESN2, CCNG1, 
ZFP36L1, SFR1, VRK2, ZNF226, HNRNPF, 
HIST1H4E, NDRG1, THAP1, HIST1H4I, HIST1H4J, 
TCF3, ZNF267, FKTN, RECQL5, KLF10, ZMYM5, 
JRKL, TKT, TRIM23, SNAI2, ZNF165, RERG, 
CDKN1A, ATF3, PNRC2, ZBED4, HIST1H3A, 






ITGB3BP, CYP24A1, HIST4H4, RBM3, ZNF638, 
HIST2H4A, TCEAL1, NOCT, FUBP1, CCNE1, 
BLZF1, INTS6, ANKRD11, NSMCE2, AKIRIN1, 
AKT3, IP6K2, NQO2, RELB, ARNTL, DDIT3, 
NABP1, HIF1A, HIST2H2BF, MAPK9, CCDC174, 
CUX1, SCAF8, GADD45A, EID3, SRSF10, TRIB3, 
PPP6R3, NR3C1, SRRT, SQSTM1, HNRNPF, 
HIST1H4E, HIST1H4I, TCF3, HIST1H4J, 
PPP4R3B, RECQL5, PPHLN1, TKT, TRNT1, 
CDKN1A, ATF3, CHML, SMARCC1, HIST1H3A, 
IRF1, RNPC3, EAF2, RBM14, NFIA
56 1.94 8.36E-05
GO CC GO:0000786~ HIST4H4, HIST1H3A, HIST1H4E, H2AFJ, 7 7.04 0.0209









HIST4H4, HIST1H3A, HIST1H4E, HIST2H4A, 





ITGB3BP, TUBB2A, RBM3, CLK1, MAGEC1, 
SFSWAP, CLK4, ARL14, INTS6, C8ORF4, 
RABGEF1, C9ORF43, AKIRIN1, FNDC3B, NQO2, 
ZNF101, L3MBTL4, RELB, SOCS4, RBKS, ARNTL, 
MRM1, DDIT3, BCL2L11, NABP1, HIF1A, USO1, 
MAPK9, SCAF8, TRAF1, CAMTA2, EID3, SRSF10, 
CACUL1, SLC38A9, SNX5, NFKBIE, SLF2, 
FAM122A, C6ORF226, PPCDC, TIMP2, SESN2, 
CCNG1, ZFC3H1, GFM2, VRK2, C1ORF50, 
HNRNPF, MTCH1, HIST1H4E, NDRG1, LETMD1, 
HIST1H4I, HIST1H4J, TCF3, RBM12B, KLF10, 
ASXL1, ZMYM5, TRIO, TKT, VAV2, ATG3, PPIF, 
CDKN1A, C1ORF116, ATF3, PNRC2, SMARCC1, 
HIST1H3A, MAP4, RIT1, EAF2, AGR2, PDCD6, 
ALG13, PPP2R3C, HIST4H4, ANKRD10, 
HIST2H4A, LATS1, DGCR14, RSRC2, FUBP1, 
CCNE1, BLZF1, NSMCE2, NFIL3, AKT3, IP6K2, 
RAP2A, TTC32, ZBTB21, CCNL1, CCT6A, 
C8ORF44-SGK3, MXD3, NUCB2, G0S2, MAPRE2, 
GADD45B, GADD45A, MAP3K13, CALD1, 
RPS15A, TRIB3, C1R, PPP6R3, FKBP1A, NR3C1, 
ZNF655, SPRR2E, TSPYL4, ZNF177, FAM46B, 
ZFP36L1, SRRT, SFR1, KLC1, SQSTM1, THAP1, 
INPP5A, PHLDA1, CCNB1IP1, PPHLN1, TECPR2, 
TRIM23, SNAI2, RCAN3, SGTB, TAB2, RPL28, 




HIST4H4, ZNF558, ZNF557, ZNF655, HIST2H4A, 
ZNF177, ZFP36L1, SRRT, BLZF1, ZNF181, 
ZNF226, RABGEF1, HIST1H4E, NFIL3, HIST1H4I, 
TCF3, HIST1H4J, ZNF267, ZNF101, TIGD1, 
ASXL1, SPTY2D1, JRKL, H2AFJ, ARNTL, MXD3, 








HIST4H4, SNX5, ARNTL, H2AFJ, HIST2H4A, 
DDIT3, ATF3, HIF1A, HIST2H2BF, HIST1H3A, 








HIST4H4, HIST1H4E, HIST2H4A, HIST1H4I, 






TRAF1, CCNE1, NRAS, CDKN1A, HIST4H4, 






NRAS, HIST4H4, HIST2H2BF, HIST1H3A, 
HIST1H4E, H2AFJ, HIST2H4A, HIST1H4I, 
HIST1H4J, CAMKK2
10 5.56 4.20E-03
KEGG hsa05322:Sy HIST4H4, HIST2H2BF, HIST1H3A, HIST1H4E, 9 6.61 7.18E-03












NRAS, CDKN1A, MAPK9, GADD45B, C8ORF44-





CCNE1, CDKN1A, GADD45B, CCNG1, SESN2, 








HIST4H4, HIST2H2BF, HIST1H3A, HIST1H4E, 









HIST4H4, HIST1H3A, HIST1H4E, MAPK9, 





HIST4H4, HIST2H2BF, HIST1H3A, HIST1H4E, 










CDKN1A, HIST4H4, HIST1H3A, HIST1H4E, 





HIST4H4, SMARCC1, HIST1H3A, HIST1H4E, 










CCNE1, CDKN1A, HIST4H4, HIST1H4E, 





HIST4H4, HIST1H3A, HIST1H4E, HIST2H4A, 





HIST4H4, HIST1H3A, HIST1H4E, HIST2H4A, 
HIST1H4I, HIST1H4J 6 6.2 0.0362
REACT
OME R-HSA-73777
HIST4H4, HIST1H3A, HIST1H4E, HIST2H4A, 





HIST4H4, HIST1H3A, HIST1H4E, HIST2H4A, 
HIST1H4I, HIST1H4J 6 6.49 0.0337








HIST4H4, HIST1H3A, HIST1H4E, HIST2H4A, 
HIST1H4I, HIST1H4J 6 6.41 0.0332
REACT
OME





HIST4H4, HIST1H3A, HIST1H4E, HIST2H4A, 





HIST4H4, HIST1H3A, HIST1H4E, HIST2H4A, 





ITGB3BP, HIST4H4, HIST1H4E, HIST2H4A, 





HIST4H4, HIST1H3A, HIST1H4E, HIST2H4A, 





HIST4H4, HIST1H3A, HIST1H4E, HIST2H4A, 





HIST4H4, HIST1H3A, HIST1H4E, HIST2H4A, 





HIST4H4, HIST1H3A, HIST1H4E, HIST2H4A, 





HIST4H4, HIST1H3A, HIST1H4E, HIST2H4A, 
HIST1H4I, HIST1H4J 6 11.76 0.0109
REACT
OME





HIST4H4, HIST1H4E, HIST2H4A, HIST1H4I, 







ITGB3BP, CEP72, E2F3, CEP78, NUP188, FER, 
HIST2H4A, MCM10, CCNE2, CCNE1, BLZF1, 
RAE1, CDKN2C, ORC5, MASTL, TPR, TOP2A, 
CCNA2, ORC3, CDK1, DSN1, ESPL1, OPTN, 
NUPL2, ESCO2, CDK2, RFC5, FGFR1OP, NSL1, 
RRM2, USO1, BUB1B, NUP43, ANAPC16, USP3, 
POLA1, AZI2, NDC1, TYMS, TUBGCP3, 
TUBGCP5, POLE2, NCAPG, HIST1H4E, FBXO5, 
FBXW11, FEN1, ERCC6L, CENPO, RAB2A, 
GINS1, CENPN, PDS5B, KIF18A, CDC23, CASC5, 
NDC80, CENPE, BIRC5, SMC2, CENPI, CDC25A, 






COPS2, CLSPN, RAD51C, NBN, HIST2H4A, 
BOD1L1, FANCI, H2AFX, CDK1, DTL, UFD1L, 
USP1, LIG3, TOPBP1, MBD4, POLB, RAD52, 
RMI1, CDK2, RFC5, UBE2N, NABP1, XPC, 
FANCD2, UBE2W, GADD45A, PPP4R2, EID3, 
BLM, USP3, POLR2K, SLF2, SLF1, KIAA0101, 
POLA1, CHEK1, FAAP20, SUMO3, ERCC8, 
POLE2, HIST1H4E, TCEA1, ACTL6A, RCHY1, 
FEN1, ERCC2, EXO1, RAD51AP1, MSH2, BRIP1, 
WHSC1, RAD54L, BRCA1, SMC3, ATRX, 
PARPBP, BRE, ZRANB3, CUL4B, SMC1A, 
61 2.28 2.82E-06







ITGB3BP, SENP5, LATS1, CCNE2, CCNE1, 
CCSAP, NSMCE2, MASTL, TPR, CCNA2, KIF14, 
CDK1, KIF11, DSN1, LIG3, HMGA2, CDK2, 
TACC1, CHMP1B, SYCP3, NSL1, MCMBP, 
BUB1B, MAPRE2, ARL8B, NUP43, SEPT9, 
ANAPC16, HAUS6, MPLKIP, USP9X, NCAPG, 
FBXO5, TNKS, NSUN2, HELLS, ERCC6L, 
CSNK1A1, PARD6B, PDS5B, CDC23, CASC5, 
NDC80, BIRC5, CENPE, SMC2, CDC25A, SMC3, 








ITGB3BP, ANAPC16, HAUS6, MPLKIP, USP9X, 
LATS1, CCSAP, NSMCE2, TNKS, MASTL, TPR, 
NSUN2, CCNA2, HELLS, ASPM, ERCC6L, 
CSNK1A1, CDK1, CENPN, KIF11, DSN1, KIF15, 
CDC23, CASC5, NDC80, BIRC5, GEM, HMGA2, 
CDK2, CDC25A, SMC3, SYCP3, NSL1, MCMBP, 










CLSPN, RAD51C, NBN, PPP4R2, BLM, CHEK1, 
HIST2H4A, SFR1, HIST1H4E, NSMCE2, H2AFX, 
FEN1, EXO1, RAD51AP1, YY1, LIG3, ZSWIM7, 
BRIP1, WHSC1, TOPBP1, RAD52, RAD54L, RMI1, 







CLSPN, RAD51C, NBN, PPP4R2, BLM, KIAA0430, 
CHEK1, HIST2H4A, HIST1H4E, H2AFX, FEN1, 
TRIP13, EXO1, RAD51AP1, MSH2, LIG3, BRIP1, 
WHSC1, TOPBP1, RAD52, RMI1, ESCO2, BRCA1, 






CLSPN, KIAA0101, NAP1L1, POLA1, CHEK1, 
MCM10, TOP1, POLE2, ORC5, FEN1, RBMS1, 
ORC3, CDK1, DTL, RMI1, RBBP6, CDK2, BRCA1, 






EID3, BLM, ZNF451, SAE1, BIRC5, NUP188, 
RAD52, SENP5, NUPL2, SMC3, BRCA1, 
NFATC2IP, NDC1, SUMO3, PHC3, TOP1, XPC, 






CENPN, KIF11, DSN1, USP9X, NDC80, BIRC5, 
CENPE, BRCA1, ESCO2, CIAO1, TOP1, NSL1, 







CDK1, NBN, BLM, FANCI, SYF2, HMGA2, CCNA2 7 7.66 0.0444






TUBB2A, NAA15, NAA16, STRN, PNISR, CLK1, 
ZNF638, SART3, CDCA7, HIST1H2BN, RAE1, 
CCNA2, PLS3, KRR1, IKBKAP, MAGI2, ZHX2, 
ESPL1, MECOM, RPTOR, ERGIC2, DCAF7, 
PTRF, MAPK6, KIAA1524, ARL8B, CRTC2, ACP6, 
NTAN1, UBA5, BCL2L1, ACP1, NAA35, PDSS2, 
ADAP1, SH3BP5L, RILPL1, RAC1, RCHY1, 
C19ORF24, TCF3, RANBP17, ZC3H15, MKI67, 
ACACA, GARS, FNIP1, FNIP2, UPF3A, SRSF3, 
SRSF5, AIDA, WDR61, PARPBP, PKP4, 
CDC42BPA, TGFBR3, PPP2R3C, SRSF1, 
CREBRF, HSF2, EEF2K, ANP32A, EPG5, MASTL, 
BRD4, TARSL2, USP15, ATF7IP, RAP2C, ERLIN2, 
KIAA0586, CCT6A, RFTN1, FMN1, PJA2, 
FANCD2, RRM2, OSBPL10, TXK, ZNF480, 
USP24, ARL4A, SRGAP2, SNAP29, EXOC8, 
POLA1, EPB41L4A, ERI1, ZNF655, MTMR2, 
SRRT, LRRTM4, DGKE, MTMR9, PER3, SNAP23, 
ACSL4, ZNF263, HIST1H2BD, PPHLN1, NUCKS1, 
HIST1H2BG, ATRN, CAPN2, APPL2, RPL28, 
MID2, RPS6KA3, DUSP3, RPL22, GSK3B, SFPQ, 
DYM, USP48, MPHOSPH6, KATNAL1, 
MPHOSPH8, SRP14, METTL21B, AP1G1, EIF5, 
RBM4, STYX, IL11, ATAT1, CDKN2C, DNAJC9, 
BPNT1, ASPM, EGFR, BCL10, RBFOX2, TWF1, 
RELB, RPS6KC1, TOPBP1, FADD, PKIA, TACC1, 
NABP1, HIF1A, HSPB8, STMN1, ACTBL2, EID1, 
ARFGAP3, MPLKIP, EID3, STAM2, SLF1, NHS, 
SESN2, AZI2, AKT1S1, PTK6, PRKRA, GMPPA, 
FBXW2, RPL4, ARHGDIB, ERCC6L, GINS1, 
PHACTR4, BRIP1, WHSC1, WIPI1, SAFB2, 
PRKAR1A, LVRN, ZNF318, FBXO32, HSPD1, 
CYB5R3, E2F3, GPBP1, ALG2, ANO1, DICER1, 
RPRM, FER, NBPF1, CASP8, LRWD1, CNTLN, 
KDM5B, CASP2, NFX1, CDK1, ARL1, DENND6A, 
KIF11, NUSAP1, IRF2BP2, ZFR, CHAMP1, CDK2, 
SDC1, TRNAU1AP, FAM120A, DDT, MAPRE2, 
EMC2, SNX19, HYPK, SLC7A6OS, HAUS6, 
HYLS1, GDAP1, RPS15A, NR3C1, NDC1, 
TSC22D1, CHD9, NSUN2, PPP4R3B, EXO1, 
WDFY3, BBOF1, NF1, RCAN1, RCAN3, ANXA5, 
UBE2Q2, SMC2, ANXA3, SMC3, SMC4, INVS, 
ZBED4, AKR1B1, JAK2, CUL4B, ALKBH3, 
ITGB3BP, RAB3GAP2, RAD51C, TMEM18, DZIP3, 
ALOXE3, PDLIM7, PTPN21, AQP7, HOOK3, 
G2E3, CD44, WWP2, RAB23, EIF2B2, YY1,
WNK1, KRT10, POLB, OPTN, FARP1, TANK, 
CEP350, CDCA7L, EPS8L2, COASY, SRSF10, 
IGF2BP2, AFAP1L1, PXK, TIPRL, VRK2, AGGF1, 
HOXA10, FBXO5, KLF5, MSTO1, SMYD3, 
NDFIP2, SMYD2, NOTCH3, FAM101B, RNF7, 
C1ORF116, CCT8, GRK5, CLSPN, COPS2, 
WASF3, CPEB2, FERMT2, VPS37A, SHOC2, 
CAMKK2, PARN, BLZF1, FANCI, ANKRD11, 
AGAP1, FAM129A, CEP112, RBM44, DSN1, 
HERC6, MBD1, RBBP6, DNAJC24, FCRLB, 
GADD45B, GADD45A, PLEK2, USP3, CEP126, 
PPFIA1, FKBP1A, CEP128, MLF1, PLCL2, 
SUMO3, GALK2, STK40, SQSTM1, NCAPG, 
DTNB, KIF21A, SPATA5, MLLT4, RBM25, PLEC, 
UBXN1, BIRC5, HNRNPDL, RAPH1, COG3, 
PAPOLA, C4ORF46, SLC16A7, PSMD12, PYGL, 
KIF20B, APBB2, ATP6V0A2, CALM1, STIL, 
ZC3HAV1, EIF5B, PI4K2B, MCM10, SMNDC1, 
GSTM3, MCOLN3, ZNF185, ORC5, MLKL, 
462 1.4 1.67E-15




PDRG1, CUTC, NQO2, CEP89, DTL, RRP8, 
NUPL2, CDKL3, STK4, ELL2, PTHLH, TNS3, 
MCMBP, SLU7, RIPK4, CSNK1G3, DST, MAP7D3, 
SEPT9, ANAPC16, ZFAND5, BLM, PNPT1, SOX4, 
SNX4, CMPK1, RASAL2, BLOC1S4, CSE1L, 
MFAP3L, STRBP, RNF14, CFLAR, PARD6B, 
GABARAPL2, RPGRIP1L, CASC5, BRCA1, 
RIMKLB, UACA, PSMC4, SLAIN2, ITGA7, WDR4, 
CPNE3, TMPO, FPGS, SMC1A, PDCD6, 
C9ORF72, HECW2, CEP57L1, PDCD2, 
NFATC2IP, SLK, MAPKAP1, TPP2, TPR, 
PPP1R14C, AKT3, ELP2, RABL6, PROSC, 
CAMSAP3, UBE2H, TBCEL, ECT2, RTTN, DAPK1, 
UBE2N, LAP3, AMH, LARP6, XPC, UBE2K, BTG1, 
KRIT1, COMMD3, BUB1B, UBE2W, PRKCZ, 
PPP4R2, USP9X, NANOS1, KIAA0101, ZNF706, 
DDTL, TYMS, TUBGCP3, MOAP1, TUBGCP5, 
NPAS3, SPRR2D, POU2F3, ENO3, ERCC2, 
TXNIP, ICA1, DNM1L, MAP1B, RUFY1, KIF18A, 
MTL5, CENPE, CENPI, MON2, UBL5, SLC17A5, 
CEP68, SP4, ANXA11, BRE, CENPV, ACTR10






TUBB2A, RPL15, NAA15, NAA16, CLK1, SART3, 
CDCA7, HIST1H2BN, CLK3, RAE1, CLK4, PATZ1, 
OGT, TIGD7, CCNA2, CDCA4, LUC7L3, ZNF101, 
KRR1, MAGI2, RCOR3, ZNF644, TIGD1, PIK3CB, 
ZNF48, LIG3, ZHX2, ZNF502, ESPL1, GEM, 
MECOM, ERGIC2, PTRF, MAPK6, JUN, 
TRAPPC2, CRTC2, ZNF611, ZNF79, ZSCAN5A, 
NTAN1, UBA5, PUS7, ADAP1, HESX1, ZNF226, 
RAC1, RCHY1, TCF3, NAT14, UNC45A, MKI67, 
PIBF1, NDC80, GCFC2, UPF3A, RERG, ZNF215, 
SRSF5, WDR61, PPP2R3C, SRSF1, ELF1, 
ZNF532, U2SURP, NAP1L1, ZNF347, CCNE1,
HSF2, ANP32A, MASTL, BRD4, USP15, ATF7IP, 
MICAL2, ZSWIM7, ZNF138, FMN1, ZNF134, 
FANCD2, RRM2, GNB5, TXK, ZNF33B, CLOCK, 
ARL4A, SRGAP2, ZNF557, HIST1H2AE, POLA1, 
ERI1, NUFIP1, ZNF367, ZNF655, MYCBP2, 
MTMR2, ZNF169, SF3B1, SFR1, TCEA1, ZNF750, 
PER3, FBXW11, FEN1, TRIP13, ZNF267, ZNF263, 
SPATA33, ZNF566, HIST1H2BD, ZNF28, NUB1, 
NUCKS1, SWAP70, ZNF771, HIST1H2BG, CS, 
ZNF770, PHF10, CAPN2, APPL2, ZNF165, ATRX, 
DUSP3, RPL22, GSK3B, SFPQ, SYF2, ZNF461, 
MPHOSPH6, MPHOSPH8, AKNA, SRP14, 
ZNF580, EIF5, RBM4, STYX, ZNF451, TCEAL1, 
TCEAL4, CDKN2C, DNAJC9, ZNF302, CTDSP1, 
ASPM, MTUS1, EGFR, BCL10, RBFOX2, DFFB, 
NEIL3, RELB, TOPBP1, GRHL2, RMI1, PKIA, 
TACC1, NABP1, DCUN1D1, HIF1A, SYCP3, 
PRCC, HSPB8, ZNF586, HMGB1, EID1, CNBP, 
MPLKIP, BBS7, SLF2, SLF1, DSCR3, SESN2, 
ATF1, EPM2AIP1, TCERG1, PTK6, HIST1H4E, 
RPL4, HELLS, GINS1, FKTN, FOXA1, BRIP1, 
WHSC1, SPRYD4, CDKN1A, ATF3, EAF1, 
ZNF317, PNRC2, DNAJB2, RNPC3, HIST1H3E, 
NBN, GPBP1, ALG2, DICER1, E2F8, SLFN5, FER, 
MBP, PRMT7, LRWD1, CASP2, KDM5B, NFX1, 
KIF14, CDK1, CCNL1, NUSAP1, IRF2BP2, 
HMGA2, CHAMP1, CDK2, TMEM38B, TRNAU1AP, 
FAM120A, NSL1, TXNRD1, EMC2, UGP2, SNX10, 
KDM6B, SLC7A6OS, HYLS1, GDAP1, DCK, 
NR3C1, TSPYL4, TSC22D1, CHD9, TFAM, CHD2, 
VPS36, NSUN2, HSPA8, EXO1, NCDN, NF1, 
RCAN1, ANXA5, SMC2, SMC3, SMC4, INVS, 
ZBED4, ZRANB2, JAK2, ZRANB3, ALKBH3, 
SCAND1, ITGB3BP, RAD51C, PDLIM7, SLC35A2, 
ATP2B1, SFSWAP, N4BP2L2, H2AFV, WWP2, 
CREB3L2, H2AFX, FAM103A1, PAN2, YY1, 
KRT10, POLB, OPTN, ESCO2, TBRG1, CDCA7L, 
SRSF10, SRSF11, CHEK1, IGF2BP2, AFAP1L1, 
PXK, VRK2, HOXA10, FBXO5, TCF25, IKZF5, 
PELI1, TKT, SMYD2, NOP10, RAD54L, NOTCH2, 
RNF7, GRK5, NCOR1, CPEB2, EID2B, FERMT2, 
SOBP, SHOC2, SENP5, ARL2BP, CAMKK2, 
PARN, BLZF1, ANKRD11, NSMCE2, TOP2A, 
IP6K2, CTBP2, DSN1, UFD1L, HERC6, SF1, 
MBD4, FAM76B, FAM76A, RAD52, MBD1, 
ZCCHC17, GADD45B, GADD45A, MECR, USP3, 
POLR2K, LARP1B, MLF1, SUMO3, ZFP36L1, 
NCAPG, THAP1, ACTL6A, RAB2A, UBXN1, 
PDS5B, BIRC5, HNRNPDL, PAPOLA, SLC50A1, 
KIF20B, APBB2, CALM1, ZC3HAV1, EIF5B, SAE1, 
PMAIP1, MCM10, CBX5, SMNDC1, TOP1, 
ZNF181, GSTM3, ORC5, LOX, ATOH7, AKIRIN1, 
CUTC, RBMS1, DTL, USP1, TOR1AIP1, RRP8, 
454 1.31 1.49E-09




NUPL2, STK4, ZNF197, FGFR1OP, MCMBP, 
SLU7, AKAP7, DST, MAP7D3, CAV2, BLM, SOX4, 
SOX6, CMPK1, CSE1L, MTCH2, C12ORF10, 
MFAP3L, STRBP, SSX2IP, SLC30A9, RNF14, 
MAFG, PARD6B, CSTF3, CSTF2, KCTD1, ATAD2, 
CASC5, HEATR1, BRCA1, PRICKLE4, UACA, 
PSMC4, WDR4, CPNE3, TMPO, SMC1A, PDCD6, 
DUT, C9ORF72, ARHGAP19, HIST2H4A, PDCD2, 
NFATC2IP, PHC3, FUBP1, RANBP9, MAPKAP1, 
TPP2, SETMAR, CDK12, TPR, RABL6, ZNF92, 
ECT2, UBE2N, LAP3, LARP6, XPC, UBE2K, 
BTG1, COMMD3, UBE2W, MSANTD4, CUX1, 
SUPT3H, PPP4R2, KIAA0101, ZNF706, TYMS, 
ERCC8, NPAS2, POU2F3, ERCC2, TXNIP, DLST, 
KAT2B, RAD51AP1, RUFY1, KIF18A, MTL5, 
CENPE, CENPI, RALGDS, UBL5, ADNP2, CEP68, 




ITGB3BP, MOCOS, EHHADH, RPL15, LPAR1, 
TPK1, CUL3, COL4A3BP, PIK3CA, DEPDC1B, 
OGT, EIF2B2, PAN2, PAN3, PIK3CB, MYH3, 
NUDT15, ESPL1, VPS41, OPTN, MECOM, FARP1, 
RPTOR, BCL2L11, TANK, PGM2, PGM3, PTRF, 
MAPK6, JUN, PUDP, MAPK9, NUP43, TRAPPC2, 
PFKFB4, UBA5, IGF2BP2, BCL2L2, CHEK1, 
BCL2L1, PPCDC, RIC1, EPHB2, TK1, GPD1L, 
NPHP3, RILPL1, STX17, RAC1, CDA, FBXO5, 
TNKS, AMD1, PELI1, OSBPL3, TGFBR2, GARS, 
ACACA, TRIO, CDC23, GAS2, NDC80, TKT, 
SMYD2, GART, NOTCH3, UPF3A, RERG, RPE, 
CCT8, SH3RF1, ENOX2, UBE2G2, FERMT2, 
LATS1, ARL2BP, CCNE2, CCNE1, PARN, 
AASDHPPT, FXN, EEF2K, ARHGAP11A, RAP2A, 
PRTFDC1, RAP2C, DSN1, POLR1D, UFD1L, 
RAB4A, HERC6, CCT6A, C8ORF44-SGK3, 
ARHGEF10, CHMP1B, PAPD4, MB21D1, 
SERPINB8, RRM2, EIF4A2, PSEN2, GNB5, 
THEM4, PARVA, SRGAP2, SERP1, BID, ATG10,
LIMS1, SORD, EXOC7, EXOC8, POLR2K, PPFIA1, 
RPL27A, UROS, RPL37, FKBP1A, ZFP36L1, 
MTMR2, RPL32, KLC1, SQSTM1, NCAPG, CHM, 
FBXW11, MLLT4, PLEC, CSNK1A1, UBXN1, 
SPATA33, SLC8A1, PDS5B, SWAP70, BIRC5, 
CAPN2, RPL28, MSRB3, RPS6KA3, DUSP3, 
311 1.41 3.15E-09




PSMD12, RPL22, PYGL, GSK3B, GFPT1, NLN, 
PAICS, CALM1, SRP14, CEP72, STIL, OCLN, 
AP1G1, EIF5, CEP78, F2RL1, STYX, EIF5B, 
SAE1, PMAIP1, PI4K2B, VCL, GSTM3, ATAT1, 
CDKN2C, SLC2A1, MLKL, BPNT1, BCL10, CEP89, 
DFFB, RELB, CORO7, FADD, NUPL2, CDO1, 
STK4, TNNT3, HIF1A, FGFR1OP, NBR1, USO1, 
AKAP7, STMN1, DST, CHMP2A, ANAPC16, 
HMGB1, CNBP, ARFGAP3, BBS7, DIAPH2, 
STAM2, SESN2, CMPK1, RASAL2, BLOC1S4, 
AKT1S1, CSE1L, PRKRA, RPL4, SEC61A1, 
TRAF3, ARHGDIB, ERCC6L, PARD6B, 
GABARAPL2, CFLAR, RPGRIP1L, FN3KRP, 
CASC5, MYL12A, VAV2, ATG3, WIPI1, KCTD7, 
CDKN1A, PLK4, PSMC4, GLS, PRKAR1A, 
DNAJB2, CPNE3, HSPD1, FPGS, SMC1A, NBN, 
PRKAG2, DICER1, ARHGAP19, PPIP5K2, RHOQ, 
FER, MKLN1, RANBP9, PRMT7, TPP2, MAPKAP1, 
CASP8, RHOD, CASP2, SEC24D, KIF14, CDK1, 
KIF11, KIF15, ECT2, CDK2, UBE2N, EIF4G2, 
ATP6V1A, EIF4G3, NSL1, NUCB2, BUB1B, 
TXNRD1, INPP4B, CUX1, SMS, UGP2, PRKCZ, 
USP9X, CALD1, ADH5, DCK, RPS15A, NR3C1, 
TPM4, FAM13B, TYMS, TUBGCP3, TFAM, 
NPAS2, MOAP1, TUBGCP5, ENO3, BRK1, 
TNRC6B, VPS36, TNRC6A, HBB, HSPA8, 
CENPO, TXNIP, SCLT1, CENPN, ICA1, DNM1L, 
KAT2B, NCDN, NF1, MAP1B, KIF18A, AHI1, 
CENPE, TPMT, ANXA5, SMC2, SMC3, CDC25A, 
RALGDS, CENPI, SMC4, CADPS, MPI, GSPT1, 
AKR1B1, JAK2, CENPU, SH3D19, CUL4B
GO CC GO:0005654~
nucleoplasm
ITGB3BP, RAD51C, FAM20B, PNISR, ZNF638, 
SART3, CUL3, HIST1H2BN, CDCA7, CLK3, 
COL4A3BP, CREB3L2, H2AFX, PATZ1, OGT, 
CCNA2, LUC7L3, LIG3, ZHX2, POLB, OPTN, 
MECOM, RPTOR, ESCO2, RFC5, DCAF7, PTRF, 
CEP350, MAPK6, JUN, MAPK9, SCAF8, COASY, 
CRTC2, SRSF10, SRSF11, CHEK1, RILPL1, 
FBXO5, RCHY1, TCF3, KLF5, GARS, SMYD3, 
CDC23, TKT, SMYD2, RAD54L, GCFC2, FNIP2, 
NOTCH3, UPF3A, SRSF3, NOTCH2, SRSF5, 
RNF7, WDR61, PARPBP, CCT8, NCOR1, 
CREBRF, SRSF1, CLSPN, COPS2, ELF1, 
FERMT2, U2SURP, VPS37A, SHOC2, TRMT10C, 
SENP5, BOD1L1, CCNE2, CCNE1, BLZF1, FANCI, 
ANKRD11, ANP32A, NSMCE2, MASTL, BRD4, 
TOP2A, DEDD2, IP6K2, ATF7IP, UFD1L, POLR1D, 
SF1, MBD4, RAD52, RBBP6, FANCD2, RRM2, 
ZNF480, RBM39, GADD45A, NSD1, CLOCK, 
ARL4A, CLUAP1, POLR2K, POLA1, ZNF367, 
FAAP20, SUMO3, SF3B1, SRRT, MRPL10, 
STK40, SQSTM1, TCEA1, ACTL6A, SNAP23, 
MLLT4, FEN1, RBM25, ZNF263, ECI2, TRMU, 
HIST1H2BD, PDS5B, PPHLN1, HIST1H2BG, 
BIRC5, HNRNPDL, COG3, RPS6KA3, DUSP3, 
PAPOLA, PSMD12, SFPQ, KIF20B, USP48, 
RBM15, CALM1, RBM4, SAE1, MCM10, TCEAL1, 
PNN, CBX5, TOP1, KLHL8, ORC5, CTDSP1, 
AKIRIN1, NQO2, ORC3, ARGLU1, RBFOX2, DTL, 
DFFB, USP1, NEIL3, RELB, TOPBP1, RRP8, 
NUPL2, GRHL2, RMI1, ELL2, PTHLH, NABP1, 
HIF1A, HSPB8, MCMBP, SLU7, MAP7D3, 
ANAPC16, EID1, HMGB1, MPLKIP, EID3, BLM, 
283 1.61 2.66E-15




STAM2, SOX4, SOX6, NR2C2, ATF1, AKT1S1, 
CSE1L, POLE2, C12ORF10, PTK6, PRKRA, 
HIST1H4E, ERCC6L, GINS1, MAFG, CSTF3, 
CSTF2, BRIP1, ATAD2, CASC5, WHSC1, BRCA1, 
SAFB2, TRNT1, CDKN1A, ATF3, EAF1, PSMC4, 
SMARCC1, WDR4, C2ORF49, FBXO32, ZNF318, 
HIST1H3E, RNPC3, SMC1A, DUT, C9ORF72, 
NBN, E2F3, GPBP1, PRKAG2, HIST2H4A, 
FAM63B, PHC3, FUBP1, PRMT7, MAPKAP1, 
CASP8, TPR, KDM5B, AKT3, CDK1, BANP, 
HMGA2, CHAMP1, ZFR, CDK2, UBE2N, LAP3, 
XPC, CUX1, KDM6B, MATR3, HYPK, SMARCAD1, 
SUPT3H, PPP4R2, HAUS6, KIAA0101, NR3C1, 
TYMS, CHD9, ERCC8, NPAS2, NPAS3, POU2F3, 
CHD2, NSUN2, TNRC6A, HSPA8, ERCC2, 
PPP4R3B, EXO1, CENPO, CENPN, KAT2B, 
RAD51AP1, MSH2, FAM188A, SMC2, SMC3, 
CDC25A, CENPI, SMC4, SP4, AKR1B1, ANXA11, 
BRE, ZRANB2, CENPV, JAK2, CUL4B, MIS18BP1, 




ITGB3BP, AKNA, IMPAD1, AP1G1, HBS1L, 
RPL15, NAA15, STRN, PI4K2B, MTHFD1L, PNN, 
ATP2B1, CUL3, CISD2, SLC16A1, CLK3, WWP2, 
SLC2A1, LRRC59, RNF149, EGFR, KRR1, 
SLC33A1, RPS6KC1, KRT10, CORO7, VPS41, 
CHPT1, ERGIC1, GCC2, TACC1, ERGIC2, 
PARP16, CEP350, LRP10, ATP2C1, NBR1, 
ACAP2, USO1, SLU7, RIPK4, STMN1, ARL8B, 
MAP7D3, CHMP2A, CAV2, ARFGAP3, BBS7, 
PNPT1, SNX4, PRRC2C, RIC1, IKBIP, MIA3, 
KIAA2013, CSE1L, MTCH2, RAC1, PRKRA, 
HIST1H4E, HLA-DPB1, RPL4, ARL6IP5, 
SEC61A1, ERCC6L, ARHGDIB, OSBPL3, MKI67, 
TGFBR1, NDC80, HEATR1, GAS2, PPIF, RERG, 
APOL2, NOTCH2, DDX55, ATP2A2, PSMC4, 
PRKAR1A, HIST1H3E, HSPD1, TMPO, ALG11, 
NCOR1, CYB5R3, SLC20A1, ALG2, ATL3, 
KIAA0430, NAP1L1, TMEM237, DNAJC10, 
NUP188, HIST2H4A, SLC26A2, MMP25, PIGK, 
SRPX, FANCI, DENND5B, FAM129A, PPP1R14C, 
CASP2, PIGA, AP3B1, KIF14, CDK1, KIF11, 
MAN1A2, KIF15, PIGT, PIGN, EIF4G2, FAM120A, 
PSEN2, AVEN, SEC23B, MATR3, BID, MFSD6, 
PRKCZ, SORD, EXOC7, GALNT7, EXOC8, 
USP9X, GDAP1, RPL27A, RPS15A, FKBP1A, 
NR3C1, ESYT1, TPM4, MYCBP2, NDC1, 
TUBGCP3, DGKE, RPL32, NCAPG, KLC1, 
BCAP29, PCSK6, ACSL4, INPP5A, HSPA8, FEN1, 
CSNK1A1, DLST, ECI2, DNM1L, NCDN, MSH2, 
NF1, CENPE, ANXA5, RPL28, ANXA3, ITPR2, 
SLC17A5, INVS, PSMD12, MBOAT7, ANXA11, 





STIL, CEP72, CEP57L1, CEP78, VPS37A, 
ARL2BP, HOOK3, CCNE1, SLC16A1, CCSAP, 
MASTL, CEP112, CDK1, CEP89, DTL, KIF15, 
ESPL1, TOPBP1, KIAA0586, CAMSAP3, 
ARHGEF10, CDK2, RTTN, ELL2, ANKRD26, 
CEP350, FGFR1OP, PSEN2, SNX10, MAP7D3, 
SNAP29, CLUAP1, PPP4R2, HAUS6, MPLKIP, 
63 2.21 6.99E-07




BBS7, HYLS1, CEP126, SLF1, CHEK1, BCL2L1, 
TUBGCP3, RILPL1, TUBGCP5, NCAPG, FBXW11, 
TBC1D31, ERCC6L, CSNK1A1, PPP4R3B, SCLT1, 
NIN, RPGRIP1L, AHI1, PIBF1, PLK4, CEP68, 





PDS5B, DTL, PPHLN1, NUSAP1, TOPBP1, 
WHSC1, CENPE, RBBP6, FAAP20, ZFR, SMC3, 
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ABSTRACT
MiR-182 expression was evaluated by qRT-PCR and in situ hybridization in 20 
tubular adenomas, 50 colorectal carcinoma (CRC), and 40 CRC liver metastases. 
Control samples obtained from patients with irritable bowel syndrome, or tumor-
matched normal colon mucosa were analyzed (n=50). MiR-182 expression increased 
????????????????????????????????????? ???????????????????????????????????????????????
in CRC liver metastases. The inverse relation between miR-182 and the expression 
of its target gene ENTPD5 was investigated by immunohistochemical analysis. We 
observed that normal colocytes featured a strong ENTPD5 cytoplasmic expression 
?????????????????????????????????????????????????????????????????????????????????
dedifferentiation of the histologic phenotype. Plasma samples from 51 CRC patients 
and controls were tested for miR-182 expression. Plasma miR-182 concentrations 
???????????????????????????????????????????????????????????????????????????????????
???????????????????????????????????????????????????? ?????????????????????????
reduced in post-operative samples after radical hepatic metastasectomy compared 
to preoperative samples. Our results strengthen the hypothesis of a central role of 
miR-182 dysregulation in colon mucosa transformation, demonstrate the concomitant 
progressive down-regulation of ENTPD5 levels during colon carcinogenesis, and 
indicate the potential of circulating miR-182 as blood based biomarker for screening 
and monitoring CRC during the follow-up.
INTRODUCTION
Colorectal cancer (CRC) is the third most common 
cancer and the third leading cause of cancer death in 
men and women in the United States [1]. Metastatic 
spread remains the ultimate cause of cancer-related death 
in most CRC cases, and 20-25% of patients present 
metastatic disease at diagnosis [2, 3]. While localized 
Oncotarget2www.impactjournals.com/oncotarget
CRC (stage I-II) is curable by surgical excision, only 
about 70% of stage III CRC cases with regional lymph 
node metastasis are curable by surgery combined with 
adjuvant chemotherapy. Metastatic disease (stage IV), 
despite improved survival due to recent advances in 
chemotherapy, is usually incurable [2, 3]. Therefore, 
it is of critical importance to understand the molecular 
alterations involved in CRC development and progression, 
and identify diagnostic and prognostic biomarkers for 
improving CRC patients’ survival [4, 5]. 
MicroRNAs (miRNAs) are non-coding RNAs 
that control gene expression at the post-transcriptional 
level [6, 7]. Numerous studies have demonstrated that 
???????????????????????????????????????????????????????
many cancer types including CRC and can be associated 
with prognosis and therapeutic outcome [8, 9]. More 
recently, owing to miRNAs stability against degradation 
????????????????????????????????????????????????????????????
miRNAs may serve as a novel class of mini-invasive 
diagnostic biomarkers has been strongly suggested [10, 
11]. Controversial data exist on miR-182 dysregulation 
in human cancer. miR-182 is up-regulated in ovarian 
cancer, melanoma, and hepatocellular carcinoma [12-
14]; conversely, miR-182 is down-regulated in gastric 
adenocarcinoma and lung cancer [15-17]. These results 
suggest a key role of miR-182 in carcinogenesis, possibly 
with different mechanisms in various cancer subtypes.
In their seminal article, Sarver and colleagues 
reported an up-regulation of miR-182 in a small series of 
CRCs by using miRNA microarray expression analysis 
[18]. Surprisingly, two following studies have not found 
any difference in the expression of miR-182 between 
tumor and normal tissue [19, 20]. More recently, miR-182 
expression has been associated to adverse CRC clinical 
characteristics and poor prognosis [21, 22]. By using a 
??????????????????????????????????????????????????????
colon mucosa, primary tumor and liver metastases of CRC 
samples, our group recently demonstrated that miR-182 
was one of the most up-regulated in the transition from 
normal colon mucosa to primary tumor. Moreover, by 
??????????????????? ???? ?????? ??????????? ????????????
????????????????????????????????????? ????????????
In the present study, we further investigated the 
involvement of miR-182 in the transformation of the 
colon mucosa and CRC progression, and also extended 
the analysis of the relationship among miR-182 expression 
???????????????????????????? ?????????????????????????
diagnostic and prognostic value of circulating miR-182 as 
a potential biomarker for CRC patients monitoring.
RESULTS
miR-182 is up-regulated during colon 
carcinogenesis and metastatic process
 ???????????????????????????????????????????????
expression in CRC [24], we investigated its expressions 
in the colic adenoma-carcinoma sequence. To this 
????? ???????? ??????????? ???? ????????? ??? ????????
????? ??????????????????????? ??????????????????????????
mucosa, 20 tubular adenomas low-grade [LG] and high-
?????? ????? ???????????????? ?????????? ?????? ?????????
known as dysplasia], and 10 early primary stages CRC. 
??? ????????? ?? ??????????? ?????????????? ??? ????????
??? ???????? ????????? ????? ??????? ??????????? ????????
t-test, p????????????????????????????????????????????
fold change; t-test, p=0.030), and in CRCs (15.2-fold 
change; t-test, p=0.020) (Figure 1A) in comparison 
to normal colic mucosa. Overall, miR-182 expression 
????????????????????????????????????????????????????????
carcinogenesis cascade (ANOVA, p<0.001). 
To study miR-182 dysregulation in CRC liver 
metastases, we investigated miR-182 expression by 
?????????????????????????????????????????????????????
????????????????????????????????????????????????????
both in primary CRCs (5.3-fold change; paired t-test, 
p<0.0001), and CRC liver metastases (7.5-fold change; 
paired t-test, p=0.005) compared to normal tissues. 
????????????????????????????????????????????????????????
miR-182 expression in comparison to primary tumors.
We also investigated miR-182 expression by ISH 
???????????????????????????????????????????????????????
overexpression in paired primary tumors and CRC liver 
metastasis in comparison to normal colon mucosa was 
observed in all the tested samples (Figure 1C). miR-182 
expression was detectable as a granular blue cytoplasmic 
staining consistently expressed by cancerous epithelia, 
whereas normal colocytes showed a negative or faint 
staining.
To further strengthen these results, we evaluated 
the prognostic impact of miR-182 expression on a large 
number of CRCs in The Cancer Genome Atlas (TCGA) 
CRC series (n=393). Interestingly, miR-182 expression 
??????????????????????????????????????????????????????
(t-test, p=0.041) or liver metastases (t-test, p=0.022) 
at diagnosis. In univariate analysis, and considering 
the median miR-182 value as a cut-off limit, miR-182 
expression levels negatively correlated with the overall 
survival of patients (Mantel-Cox log-rank test, p=0.035) 
(data not shown).
Oncotarget3www.impactjournals.com/oncotarget
Figure 1: miR-182 is up-regulated during colon carcinogenesis. (A)? ?????????????????? ??????????????????????????????????
??????????????????????????????????????????????????????????????????????????????????????(B) miR-182 expression was evaluated by 
??????????????????????????????????????????????????????????????????????????????????????????????(C) Representative ISH evaluation of 
miR-182 in matched tissue sections of normal colon, primary tumor and metastatic CRC (N= normal colon mucosa; K= primary CRC). 
????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????
?????????????????????????????t test); *p<0.05; **p????????????????????????????????????????????????????????????????? ????????????????






test); *p<0.05; **p<0.01. Immunohistochemical scores: black = score 3 (% positive cases), dark gray = score 2, light gray = score 1, white 
???????????????????????????????????????????????????????????????????????????????????????? ?????????????????
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miR-182 targets ENTPD5 during colon 
carcinogenesis
By means of luciferase mutagenesis reporter assay 
?????????????????????????????????????????????????????
??????? ????? ???????? ??????????? ????????? ???? ????????
???? ????? ??? ???????? ??????????? ??? ???????? ??????
???????????? ???? ?????????????????????????? ???????????
?????????????? ???????????????????????????????????????
restored luciferase expression, thus demonstrating a direct 
???????????????????? ?????????????????? ?????????????
transcript (Figure 2A).
??? ???????? ????? ??????? ??? ???????? ??????? ???
????????????????????????????????????????????????????
colorectal carcinogenesis in a series of 20 normal colic 
???????????????????????????????????????????????????
?????????????????????????????????? ????? ????????????????
????????? ??????? ??????? ???????????? ???????????????
????????????????????????????????????? ?????????????????
was observed along with the dedifferentiation of the 




liver metastases (20 matched cases). By using qRT-
???????? ?????????????????????????????????????????
?????? ?? ??????????? ???????????????? ??? ??????? ?????
normal colon mucosa, through primary CRC tumor to 
liver metastases (both p<0.001; Figure 2C). Overall, our 
??????????????????????????????????????????????????????????
????????????? ??????????????? ??? ???????? ???????????????
CRC, as compared to normal tissue (Figure 2), thus 
?????????? ???? ????????????? ???????? ???????? ???? ????
target. 
Evaluation of plasma miR-182 levels in CRC 
patients
We hypothesized that the higher miR-182 expression 
??????????? ??????????????????? ???????? ?????? ?????????
the miR-182 expression in the plasma of CRC patients. 
We thus analyzed miR-182 plasma levels in 10 healthy 
volunteers, 10 patients with colic adenomas at endoscopy, 
10 early stages (stages I and II) and 10 late stages (stages 
III and IV) CRC patients.
????????????????????????????????????????????????
higher in CRC patients than in healthy controls (3.2-fold 
change; t-test, p=0.008) or patients with colic polyps at 
endoscopy (1.14-fold change; t-test, p=0.013) (Figure 3A). 
Considering tumor staging, miR-182 plasma expression in 
??????????????????????????????????????????????????????
higher than in normal controls (t-test, p=0.041 and 
p=0.003, respectively; Figure 3B).
We also evaluated miR-182 plasma levels before and 
???????????????????????????????????????????????????????
182 concentration was analyzed in paired pre- and post-
operative samples from 11 CRC patients who underwent 
curative liver metastasectomy. We observed that miR-182 
????????????????????????????????????????????????????????
surgery (paired t-test, p=0.020; Figure 3C).
DISCUSSION
The results of the present study can be summarized 
??????????????? ???????????????????????????????????????????
colon carcinogenesis, and is associated to CRC patients 
prognosis; ii) miR-182 exerts a suppressive regulation 
??? ???????? ??????????? ?????? ?????????? ????????? ???
colon carcinogenesis; iii) miR-182 up-regulation can be 
detected in CRC plasma samples, and is therefore eligible 
as a novel diagnostic and non-invasive follow-up marker.
Reports on miR-182 involvement in human cancer 
?????????? ????????????????????????????????????????????????????????????????(A) miR-182 plasma levels were analyzed in 10 
healthy volunteers, 10 patients with colic adenomas at endoscopy, 10 early stages (stages I and II) and 10 late stages (stages III and IV) CRC 
patients. (B) miR-182 plasma expression in advanced CRC patients and in early CRC patients. (C)?????????????????????????????????????
and after curative liver metastasectomy (p????????????????????????????????t test); *p<0.05; **p<0.01. nRQ, normalized Relative Quantity. 
??????????????????????? ????????????????
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have been discordant. For instance, miR-182 aberrant 
expression has been associated to tumor progression in 
melanoma, endometrial cancer and prostate carcinoma 
[13, 16, 25, 26]; in contrast, a tumor-suppressive role has 
been established in gastric adenocarcinoma, where miR-
182 overexpression leads to the suppression of tumor cell 
growth [15].
More recently, miR-182 enhanced expression has 
been associated to adverse CRC clinical characteristics 
and poor prognosis [21, 22]. miR-182 prognostic impact 
is also supported by our elaboration of data from TCGA 
CRC cohort showing higher miR-182 expression in more 
advanced stages of CRC, and shorter survival in patients 
???????????????????????????????????????????????????????
consistent with miR-182 plasma levels, which are higher 
in advanced CRC patients.
MiR-182 dysregulation in CRC has been associated 
??? ???? ?????????? ??? ???? ???????????????? ??????? ????
1. Moreover, anti-miR-182 exerts a transcriptional 
??????????????????????????????????????????????? ????
????????????????????????????????????????????????????????
post-transcriptional regulatory networks with miRNAs 
differentially expressed in the transition from normal 
mucosa through primary tumor to metastases. We 
observed that miR-182 is one of the most up-regulated 
miRNAs and, according to the reconstructed networks, 
has several putative target genes, some of which are 
????????????? ??????????????? ?????????? ??? ???? ?????
comparisons [23]. Among these predicted interactions, 
a few have been already validated in cancer. For 
instance, it has been demonstrated that miR-182 acts 
as an oncogenic miRNA by interacting and negatively 
??????????????????????????????????????????????????????
???????????????????????????????????????????????????????
???? ????????? ?????? ???????????? ???? ??????????? ???
cancer has been demonstrated but their interaction with 




mRNA and protein level. Our results are in line with that 
recently published by Mikula et al. who showed that both 
??????? ??????????????????????????????????????????????
during the transition from normal colon mucosa, through 
adenoma, to adenocarcinoma [30]. 
??????????????????????????????????????????????
enzymes and has been alternatively linked, depending 
??? ???? ?????????? ?????? ????? ??????? ?????????? ??? ????
consumption as well as protein folding [31]. Moreover, the 
expression of its mutated counterpart, better known as mt-
??????????????????????????????????????????????????????
activity, thus suggesting the proactive function of this 
enzyme as a proto-oncoprotein in tumor development [32]. 
However, owing to the discrepant results obtained in the 
different tumor types, the molecular functions played by 
?????????????????????????????????????????????????????
??????????????????????????????????????????????????
expression in CRC patients. Many studies have evaluated 
the feasibility of circulating miRNAs for detecting early 
stage cancer and as a prognostic/predictive marker. Ng 
et al. recently faced this issue by comparing miRNAs 
????????????????????????????????????????????????????????
miRNAs that were differentially expressed in both groups 
of samples [19]. MiR-17-3p and miR-92, belonging to the 
????????????????????????????????????????????????????
were validated as differentially expressed in CRC plasma 
and tissue, in comparison to their normal counterparts 
?????? ??? ?????? ????????? ???? ??????????? ????????????
miR-601 and miR-760 were also suggested as potential 
diagnostic biomarkers of adenomas and CRC by the same 
group. Combining miR-29a, miR-92a, and miR-760, the 
detection sensitivity of early stages of CRC was further 
improved [33]. Another study which undertook a genome-
????? ?????? ????????? ??? ???????? ?????????? ?????????
miR-19a, miR-19b, miR-29a, and miR-335 as being able 
to differentiate CRC patients from healthy individuals, 
while miR-18a could do so also between advanced 
adenomas and healthy individuals [34].
In the present report, we pinpointed miR-182 plasma 
levels evaluation as a promising approach to enhance the 
repertoire for non-invasive CRC monitoring and screening. 
The main limitation of our analyses is the limited 
samples size, which affects any statistical evaluation of 
circulating miR-182 expression and its relationship to 
clinicopathological variables. Nevertheless, this study has 
????????????????????????????????????????????????????????????
involvement of miR-182 in CRCs indicates its potential to 
be developed into a diagnostic marker for these patients. 
Secondly, miR-182 alone or in combination with its target 
????????????????????????????? ???????????????????????
marker for the monitoring of relapse of CRC patients. 
Thirdly, high miR-182 expression in advanced CRCs 
suggests that this miRNA could be an ideal candidate 
target for CRC treatment, though its diagnostic impact 
should be further tested in larger series of CRC patients.
MATERIAL AND METHODS
Patients
A total of 240 histopathological and 51 plasma 
????????????????????????????????????????????????????????
were considered and included in this study, as schematized 
in Table 1.
All the histopathological samples were 
???????????????? ?????????? ????? ???? ????? ??? ???? ?????????
?????????? ?? ?????????????? ????? ??? ???? ??????????? ???
????????????????????????????????????????????????????????
from patients with different types of sporadic colonic 
?????????????????????????????????? ???????????????????????
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????????? ???? ????????????????????????????? ??????????
I-II CRCs. Another 30 normal colonic mucosa biopsy 
samples were obtained from patients who underwent 
colonoscopy for irritable bowel syndrome. 
A further series of 40 stage IV CRCs were 
considered, and the following samples collected: i) 
normal colic mucosa taken at a minimum distance of 10 
centimeters from the primary tumor site; ii) primary CRC; 
iii) CRC liver metastasis. Tumor characteristics were 
obtained both from the gross description of the specimen, 
as recorded at the time of surgery, and from the original 
histopathology report.




and at coloscopy from 10 patients with colic adenomas, 
10 early stages (stages I and II) and 10 late stages (stages 
III and IV) CRC patients. A series of 11 stage IV CRC 
patients was also considered, and plasma samples were 
available at surgery and after 30 days from radical hepatic 
metastasectomy. 
????????? ????? ?? ?????? ???????? ??? ?? ???????????
colorectal cancer syndrome and which underwent 
???????????? ??????????? ????? ?????????? ???? ???????
???????????????????????????????????????????????????????
the study on histopathological material (n. 57841 




NCI and NHGR were explored (15th February 2014) for 
miR-182 expression in the TCGA colorectal cancer series 
[35]. Information about TCGA and the investigators and 
institutions that constitute the TCGA research network can 
be found at “http://cancergenome.nih.gov”.
RNA isolation
Biopsy and tissue samples were manually 
microdissected to ensure that each sample contained at 
least 80% of tumor cells. The percentage of the target 
lesion as obtained by manual microdissection was 
further validated on an adjunctive hematoxylin and eosin 
histology section. Total RNA was extracted using the 
RecoverAll kit (Ambion, Austin, TX), according to the 
manufacturer’s instructions.
In plasma samples, 500 μl of human plasma was 
thawed on ice and lysed with an equal volume of 2X 
?????????????????????????????????????????????????????????
of sample-to-sample variation in RNA isolation, synthetic 
C. elegans miRNAs cel-miR-39, cel-miR-54, and cel-
miR-238 (synthetic RNA oligonucleotides synthesized 
by Qiagen) were added (as a mixture of 7 pg/pl of each 
oligonucleotide) to each denatured sample (i.e., after 
??????????????????????????????????????????????????????
with the exception of cel-miR-238, which was added after 
??????????????????????? ??????????????? ????????????
???????????????????????? ??????????????????????????????????
samples (Ambion). RNA was eluted with 50 μl of RNase-
free H2O.
????????????????
RNA extraction and quality controls were performed 
as previously described [23].
???????????????????????????????????????????????
synthesis using the SuperScript™ II Reverse Transcriptase 
kit and Taqman Assay (Invitrogen by Life Technologies 
?????? ??????????????????????????????????????????? ?????
To study mature hsa-miR-182 expression, the TaqMan 
MicroRNA Reverse Transcription Kit (Invitrogen) was 
used according to the manufacturer’s instructions [23].
All reactions were run in triplicate, including no 
template controls, in a LightCycler 480 Real-Time System 
???????????????????? ??????????????????????????????
expression was calculated using the comparative Ct 
method, and the fold change was expressed as 2?????.
For plasma samples, normalization was reached 
???????????????????????????????????????????????
Samples # patients Normal colon ?????? ?????? CRC CRC liver metastasis Techniques applied
???????????
biopsies
40 10 10 10 10 - ???????????? ??????
80 20 20 20 20 - ??????????????
Surgical 
specimens
20 20 - - 20 20 ???????????? ??????
20 20 - - 20 20
???????? ???? ???? ????
??????
ISH for miR-182
?????? 51 10 10 31 ???????????? ??????






using a median normalization procedure, as previously 
?????????? ???? ????? ???????????????????????????????????
the Ct values obtained for the three spiked-in C. elegans 
miRNAs and for hsa-miR-16 were averaged to generate 
SpikeIn_Average_Ct values. The median of the SpikeIn_
Average_Ct values obtained from all of the samples to be 
compared was next calculated (designated as the Median_
SpikeIn_Ct value). The hsa-miR-182 raw Ct in a given 
sample was adjusted as follows: Normalized_Ct value for 
the miRNA in the sample = Raw_Ct value - [(SpikeIn_
Average_Ct value of the given sample) - (Median_
SpikeIn_Ct value)]. All reactions were run in triplicate, 
including no-template controls.
???????????????????????????????
Locked nucleic acid (LNA) probes with 
complementarity to 21-bp sections of miR-182 were 
??????????????????????????????????????????????????????
?????????????????????????????????????????????????????
with ISH protease 1 (Ventana Medical Systems, Milan, 
Italy) and ISH performed as described, with minor 
????????????? ??????????????? ??????????????????????????
scrambled LNA probes were used as controls.
?????????????????????????
???????? ?????? ????????????? ???? ???????? ???? ???
??????????? ?????????? ?????????????????????? ?????????
construct with mutations in the seed sequence of miR-
182 binding was synthesized using QuickChange Site-
??????????????????????????????????????????????????????
??????????????????????????????????????????????????
miR-182 or non-target RNA (Tema ricerca, Bologna, Italy) 
as negative control, in triplicate. Luciferase and Renilla 
activity were measured 30 h after transfection using the 
???????????????????? ????????????????????????????????
to the manufacturer’s instructions. Three independent 
experiments were performed and the data are presented as 
???? ????????????????????????????????????? ???????????????
to Renilla activity as relative light unit (RLU).
????????????????????
?????????????????????????????????????????????????
by t-test, paired t-test and ANOVA, as appropriate. IHC 
data were evaluated by Kruskal-Wallis test for trend. 
Survival analysis on TCGA data was carried out by 
applying the Log-rank Mantel-Cox test. The statistical 
analysis was performed using STATA software (Stata 
Corporation, College Station, Texas, USA).
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